Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children

Downloaded from https://aidsinfo.nih.gov/guidelines on 2/26/2019

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
# Bacterial Infections

## Dosing Recommendations for Prevention and Treatment of Invasive Bacterial Infections

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>S. pneumoniae and other invasive bacteria</strong></td>
<td>• Pneumococcal, meningococcal, and Hib vaccines</td>
<td>• TMP-SMX 75/375 mg/m² body surface area per dose by mouth twice daily</td>
<td>See Figures 1 and 2 for detailed vaccines recommendations.</td>
</tr>
<tr>
<td></td>
<td>• IVIG 400 mg/kg body weight every 2–4 weeks</td>
<td></td>
<td>Vaccines Routinely Recommended for Primary Prophylaxis. Additional Primary Prophylaxis Indicated For:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Hypogammaglobulinemia (that is, IgG &lt;400 mg/dL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Criteria for Discontinuing Primary Prophylaxis:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Resolution of hypogammaglobulinemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Criteria for Restarting Primary Prophylaxis:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Relapse of hypogammaglobulinemia</td>
</tr>
<tr>
<td><strong>Secondary Prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>S. pneumoniae and other invasive bacteria</strong></td>
<td>• TMP-SMX 75/375 mg/m² body surface area per dose by mouth twice daily</td>
<td>• IVIG 400 mg/kg body weight every 2–4 weeks</td>
<td>Secondary Prophylaxis Indicated:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• &gt;2 serious bacterial infections in a 1-year period in children who are unable to take cART</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Criteria for Discontinuing Secondary Prophylaxis:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Sustained (≥ 3 months) immune reconstitution (CD4 percentage ≥25% if ≤6 years old; CD4 percentage ≥20% or CD4 count &gt;350 cells/mm³ if &gt;6 years old)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Criteria For Restarting Secondary Prophylaxis:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• &gt;2 serious bacterial infections in a 1-year period despite cART</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bacterial pneumonia; S. pneumoniae; occasionally S. aureus, H. influenzae, P. aeruginosa</strong></td>
<td>• Ceftriaxone 50–100 mg/kg body weight per dose once daily, or 25–50 mg/kg body weight per dose twice daily IV or IM (max 4 g/day), or</td>
<td>• Cefuroxime, 35–50 mg/kg body weight per dose 3 times daily (max 4–6 g/day) IV</td>
<td>For children who are receiving effective cART, have mild or no immunosuppression, and have mild to moderate community-acquired pneumonia, oral therapy option would be amoxicillin 45 mg/kg body weight per dose twice daily (maximum dose: 4 g per day). Add azithromycin for hospitalized patients to treat other common community-acquired pneumonia pathogens (M. pneumoniae, C. pneumoniae). Add clindamycin or vancomycin if methicillin-resistant S. aureus is suspected (base the choice on local susceptibility patterns). For patients with neutropenia, chronic lung disease other than asthma (e.g., LIP, bronchiectasis) or indwelling venous catheter, consider regimen that includes activity against P. aeruginosa (such as ceftazidime or cefepime instead of ceftriaxone). Consider PCP in patients with severe pneumonia or more advanced HIV disease. Evaluate for tuberculosis, cryptococcosis, and endemic fungi as epidemiology suggests.</td>
</tr>
<tr>
<td></td>
<td>• Cefotaxime 40–50 mg/kg body weight per dose 4 times daily, or 50–65 mg/kg body weight 3 times daily (max 8–10 g/day) IV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key to Acronyms:** cART = combination antiretroviral therapy; CD4 = CD4 T lymphocyte; IgG = immunoglobulin G; IM = intramuscular; IV = intravenous; IVIG = intravenous immune globulin; LIP = lymphocytic interstitial pneumonia; PCP = Pneumocystis jirovecii pneumonia; TMP-SMX = trimethoprim-sulfamethoxazole
<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>Not routinely recommended</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Secondary Prophylaxis</strong></td>
<td>Not routinely recommended but can be considered for frequent severe recurrences.</td>
<td>N/A</td>
<td>Secondary Prophylaxis Indicated:  • Frequent or severe recurrences</td>
</tr>
<tr>
<td></td>
<td><strong>Fluconazole:</strong></td>
<td></td>
<td>Criteria for Discontinuing Secondary Prophylaxis: • When CD4 count or percentage has risen to CDC immunologic Category 2 or 1</td>
</tr>
<tr>
<td></td>
<td>• Fluconazole 3–6 mg/kg body weight daily (maximum 200 mg) by mouth, or itraconazole oral solution, 2.5 mg/kg body weight/dose twice daily</td>
<td></td>
<td>Criteria for Restarting Secondary Prophylaxis: • Frequent severe recurrences</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td><strong>Oropharyngeal:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fluconazole 6–12 mg/kg body weight (maximum 400 mg/dose) by mouth once daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clotrimazole troches, 10-mg troche by mouth 4–5 times daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Nystatin suspension 4–6 mL by mouth 4 times daily, or 1–2, 200,000-unit flavored pastilles by mouth 4–5 times daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment Duration:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 7 to 14 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Esophageal Disease:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fluconazole 6–12 mg/kg body weight by mouth once daily (maximum dose: 600 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Itraconazole oral solution, 2.5 mg/kg body weight/dose by mouth twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment Duration:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Minimum of 3 weeks and for at least 2 weeks following the resolution of symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oropharyngeal (Fluconazole-Refractory):</strong></td>
<td></td>
<td>Itraconazole oral solution should not be used interchangeably with itraconazole capsules. Itraconazole capsules are generally ineffective for treatment of esophageal disease.</td>
</tr>
<tr>
<td></td>
<td>• Itraconazole oral solution 2.5 mg/kg body weight/dose by mouth twice daily (maximum 200–400 mg/day)</td>
<td></td>
<td>Central venous catheters should be removed, when feasible, in children with HIV with fungemia.</td>
</tr>
<tr>
<td></td>
<td><strong>Esophageal Disease:</strong></td>
<td></td>
<td>In uncomplicated catheter-associated C. albicans candidemia, an initial course of amphotericin B followed by fluconazole to complete treatment can be used (use invasive disease dosing).</td>
</tr>
<tr>
<td></td>
<td>• Amphotericin B (deoxycholate) 0.3–0.7 g/kg body weight IV once daily</td>
<td></td>
<td>Voriconazole has been used to treat esophageal candidiasis in a small number of immunocompromised children without HIV.</td>
</tr>
<tr>
<td></td>
<td><strong>Echinocandins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Anidulafungin:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged 2–17 Years: Loading dose of 3 mg/kg body weight/daily and then maintenance at 1.5 mg/kg body weight/dose IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged ≥18 Years: 200-mg loading dose, then 100 mg/dose daily IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Caspofungin:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Infants Aged &lt;3 Months: 25 mg/m² BSA/dose daily IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged 3 Months–17 Years: 70 mg/m²/day IV loading dose followed by 50 mg/m²/day IV (maximum 70 mg). <strong>Note:</strong> Dosing of caspofungin for children should be based on body surface area.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged ≥18 Years: 70-mg loading dose IV, then 50 mg/dose daily IV</td>
<td></td>
<td>Conversion to oral voriconazole should be at 9 mg/kg body weight/dose orally every 12 hours.</td>
</tr>
<tr>
<td></td>
<td><strong>Central Venous Catheters:</strong></td>
<td></td>
<td><strong>Children aged ≥12 years and weighing at least 40 kg can use adult dosing (load voriconazole 6 mg/kg body weight/dose every 12 hours IV on day 1, followed by 4 mg/kg body weight/dose every 12 hours IV. Conversion to oral therapy at 200 mg every 12 hours by mouth).</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Echinocandins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Anidulafungin:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged 2–17 Years: Loading dose of 3 mg/kg body weight/daily and then maintenance at 1.5 mg/kg body weight/dose IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged ≥18 Years: 200-mg loading dose, then 100 mg/dose daily IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Caspofungin:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Infants Aged &lt;3 Months: 25 mg/m² BSA/dose daily IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged 3 Months–17 Years: 70 mg/m²/day IV loading dose followed by 50 mg/m²/day IV (maximum 70 mg). <strong>Note:</strong> Dosing of caspofungin for children should be based on body surface area.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged ≥18 Years: 70-mg loading dose IV, then 50 mg/dose daily IV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Dosing Recommendations for Prevention and Treatment of Candidiasis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment, continued</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Micafungin:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Note:</strong> In the United States, optimal dosing for children is not yet established, and there is no pediatric indication yet. Studies indicate linear PK; age and clearance are inversely related (see recommended doses below).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Neonates:</strong> Up to 10–12 mg/kg body weight/dose daily IV may be required to achieve therapeutic concentrations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Infants &lt;15 kg body weight, 5–7 mg/kg body weight/dose daily IV</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Children ≤40 kg body weight and aged 2–8 years, 3–4 mg/kg body weight/dose daily IV</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Children ≤40 kg body weight and aged 9–17 years, 2–3 mg/kg body weight/dose daily IV</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Children &gt;40 kg body weight, 100 mg/dose daily IV</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>IV Fluconazole:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Children:</strong> 6–12 mg/kg body weight/dose daily for infants and children of all ages (maximum dose: 600 mg daily).</td>
<td></td>
</tr>
<tr>
<td><strong>Invasive Disease</strong></td>
<td><strong>Echinocandin Recommended</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Critically ill</strong></td>
<td><strong>Anidulafungin:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Aged 2–17 Years:</strong> Load with 3 mg/kg body weight/daily dose IV and then maintenance dose at 1.5 mg/kg body weight once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Aged ≥18 Years:</strong> 200-mg loading dose, then 100 mg once daily</td>
<td></td>
</tr>
<tr>
<td><strong>Caspofungin:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Infants Aged &lt;3 Months:</strong> 25 mg/m² BSA/dose once daily IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Aged 3 months–17 years:</strong> 70 mg/m² BSA/day loading dose followed by 50 mg/m² once daily (maximum 70 mg). <strong>Note:</strong> Dosing of caspofungin in children should be based on body surface area.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Aged ≥18 Years:</strong> 70-mg loading dose, then 50 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Anidulafungin in Children Aged 2–17 Years:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Loading dose of 3 mg/kg body weight/once daily followed by 1.5 mg/kg body weight/once daily (100 mg/day maximum).</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Fluconazole Dosing Considerations:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>If a neonate’s creatinine level is &gt;1.2 mg/dL for &gt;3 consecutive doses, the dosing interval for fluconazole 12 mg/kg body weight may be prolonged to one dose every 48 hours until the serum creatinine level is &lt;1.2 mg/dL.</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Aged ≥18 Years:</strong> 400 mg/dose once daily (6 mg/kg body weight once daily).</td>
<td></td>
</tr>
</tbody>
</table>
### Dosing Recommendations for Prevention and Treatment of Candidiasis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment, continued</td>
<td>Micafungin:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• <strong>Note:</strong> In the United States, optimal dosing for children is not yet established, and there is no pediatric indication yet. Studies indicate linear PK; age and clearance are inversely related (see recommended doses below).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Neonates: Up to 10–12 mg/kg body weight/dose daily IV may be required to achieve therapeutic concentrations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Infants &lt;15 kg body weight: 5–7 mg/kg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Children ≤40 kg body weight and aged 2–8 years: 3–4 mg/kg body weight/dose daily IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Children ≤40 kg body weight and aged 9–17 years: 2–3 mg/kg body weight/dose daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Children &gt;40 kg body weight: 100 mg/dose daily IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment Duration:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Based on presence of deep-tissue foci and clinical response; in patients with candidemia, treat until 2 weeks after last positive blood culture.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Not critically ill</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fluconazole Recommended:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 12 mg/kg body weight/dose daily IV (maximum dose: 600 mg) for infants and children of all ages</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Avoid fluconazole for <em>C. krusei</em> and <em>C. glabrata</em>, avoid echinocandin for <em>C. parapsilosis</em>.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment Duration:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Based on presence of deep-tissue foci and clinical response; in patients with candidemia, treat until 2 weeks after last positive blood culture.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key to Abbreviations:** BSA = body surface area; CD4 = CD4 T lymphocyte; CDC = Centers for Disease Control and Prevention; IV = intravenous; PK = pharmacokinetic
### Coccidioidomycosis (Last updated November 6, 2013; last reviewed November 6, 2013)

#### Dosing Recommendations for Prevention and Treatment of Coccidioidomycosis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>Primary prophylaxis not routinely indicated in children.</td>
</tr>
<tr>
<td><strong>Secondary Prophylaxis</strong></td>
<td>Fluconazole 6 mg/kg body weight (maximum 400 mg) by mouth once daily</td>
<td>Itraconazole 2–5 mg/kg body weight (maximum 200 mg) by mouth per dose twice daily</td>
<td>Lifelong secondary prophylaxis with fluconazole for patients with meningitis or disseminated disease in the immunocompromised patient is recommended. Secondary prophylaxis should be considered after treatment of milder disease if CD4 count remains &lt;250 cells/mm³ or CD4 percentage &lt;15%.</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td><strong>Severe Illness with Respiratory Compromise due to Diffuse Pulmonary or Disseminated Non-Meningitic Disease:</strong></td>
<td><strong>Severe Illness with Respiratory Compromise Due to Diffuse Pulmonary or Disseminated Non-Meningitic Disease (If Unable to Use Amphotericin):</strong></td>
<td>Surgical debridement of bone, joint, and/or excision of cavitary lung lesions may be helpful. Itraconazole is the preferred azole for treatment of bone infections. Some experts initiate an azole during amphotericin B therapy; others defer initiation of the azole until after amphotericin B is stopped. For treatment failure, can consider voriconazole, caspofungin, or posaconazole (or combinations). However, experience is limited and definitive pediatric dosages have not been determined. Options should be discussed with an expert in the treatment of coccidioidomycosis. Chronic suppressive therapy (secondary prophylaxis) with fluconazole or itraconazole is routinely recommended following initial induction therapy for disseminated disease and is continued lifelong for meningal disease. Therapy with amphotericin results in a more rapid clinical response in severe, non-meningal disease.</td>
</tr>
<tr>
<td></td>
<td>• Amphotericin B deoxycholate 0.5–1.0 mg/kg body weight IV once daily, until clinical improvement.</td>
<td>• Fluconazole 12mg/kg body weight (maximum 800 mg) per dose IV or by mouth once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• A lipid amphotericin B preparation can be substituted at a dose of 5 mg/kg body weight IV once daily (dosage of the lipid preparation can be increased to as much as 10 mg/kg body weight IV once daily for life-threatening infection).</td>
<td>• Treatment is continued for total of 1 year, followed by secondary prophylaxis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• After the patient is stabilized, therapy with an azole (fluconazole or itraconazole) can be substituted and continued to complete a 1-year course of antifungal therapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meningal Infection:</strong></td>
<td>Fluconazole 12 mg/kg body weight (maximum 800 mg) IV or by mouth once daily followed by secondary lifelong prophylaxis.</td>
<td><strong>Meningal Infection (Unresponsive to Fluconazole):</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Mild-to-Moderate Non-Meningal Infection (e.g., Focal Pneumonia):</strong></td>
<td>Fluconazole 6–12 mg/kg body weight (maximum 400 mg) per dose IV or by mouth once daily.</td>
<td><strong>Itraconazole 2–5 mg/kg body weight per dose (maximum dose 200 mg) per dose IV or by mouth 3 times daily for 3 days, then 2–5 mg/kg body weight (maximum dose 200 mg) by mouth per dose twice daily thereafter.</strong></td>
<td>Duration of treatment determined by rate of clinical response.</td>
</tr>
</tbody>
</table>
| **Key to Abbreviations:** CD4 = CD4 T lymphocyte; IV = intravenous

Guidelines for the Prevention and Treatment of Opportunistic Infections In HIV-Exposed and HIV-Infected Children 5

Downloaded from https://aidsinfo.nih.gov/guidelines on 2/26/2019
## Cryptococcosis

*Last updated November 6, 2013; last reviewed November 6, 2013*

### Dosing Recommendations for Prevention and Treatment of Cryptococcosis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>Not recommended</td>
<td>Not recommended</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| **Secondary Prophylaxis** | * Fluconazole 6 mg/kg body weight (maximum 200 mg) by mouth once daily | * Itraconazole oral solution 5 mg/kg body weight (maximum 200 mg) by mouth once daily | **Secondary Prophylaxis Indicated:**
  - Documented disease  
  **Criteria For Discontinuing Secondary Prophylaxis**
  * If *All* of the Following Criteria are Fulfilled:  
    - Age ≥6 years  
    - Asymptomatic on ≥12 months of secondary prophylaxis  
    - CD4 count ≥100 cells/mm³ with undetectable HIV viral load on cART for >3 months  
  **Criteria for Restarting Secondary Prophylaxis:**
    - CD4 count <100/mm³ |
| **Treatment**       | **CNS Disease** **Acute Therapy (Minimum 2-Week Induction Followed by Consolidation Therapy):**
  - Amphoterin B deoxycholate 1.0 mg/kg body weight (or liposomal amphoterin B 6 mg/kg body weight) IV once daily **PLUS** fluocytosine 25 mg/kg body weight per dose by mouth given 4 times daily |
|                     | **CNS Disease** **Acute Therapy (Minimum 2-Week Induction Followed by Consolidation Therapy):**
  - Liposomal amphoterin B, 6 mg/kg body weight IV once daily, or Amphoterin B Lipid Complex, 5 mg/kg body weight IV once daily, or Amphoterin B deoxycholate, 1.0–1.5 mg/kg body weight IV once daily **alone or B. in combination** with high-dose fluconazole (12 mg/kg body weight on day 1 and then 10–12 mg/kg body weight [max 800 mg] IV). **Note:** Data-driven pediatric dosing guidelines are unavailable for fluconazole with use of such combination therapy. |

In patients with meningitis, CSF culture should be negative prior to initiating consolidation therapy. Overall, *in vitro* resistance to antifungal agents used to treat cryptococcosis remains uncommon. Newer azoles (voriconazole, posaconazole, ravuconazole) are all very active *in vitro* against *C. neoformans*, but published clinical experience on their use for cryptococcosis is limited.
<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment, continued</strong></td>
<td><strong>Consolidation Therapy (Followed by Secondary Prophylaxis):</strong></td>
<td><strong>If Amphotericin B-Based Therapy Not Tolerated:</strong></td>
<td>Liposomal amphotericin and amphotericin B lipid complex are especially useful for children with renal insufficiency or infusion-related toxicity to amphotericin B deoxycholate. Liposomal amphotericin and amphotericin B lipid complex are significantly more expensive than amphotericin B deoxycholate.</td>
</tr>
<tr>
<td></td>
<td>• Fluconazole 12 mg/kg body weight on day 1, then 10–12 mg/kg body weight (max 800 mg) once daily IV or by mouth for a minimum of 8 weeks</td>
<td>• Fluconazole, 12 mg/kg body weight on day 1 and then 10–12 mg/kg body weight (maximum 800 mg) IV or by mouth once daily <strong>PLUS</strong> flucytosine, 25 mg/kg body weight per dose by mouth given 4 times daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Localized Disease, Including Isolated Pulmonary Disease (CNS Not Involved):</strong></td>
<td><strong>Consolidation Therapy (followed by secondary prophylaxis):</strong></td>
<td>Liquid preparation of itraconazole (if tolerated) is preferable to tablet formulation because of better bioavailability, but it is more expensive. Bioavailability of the solution is better than the capsule, but there were no upfront differences in dosing range based on preparation used. Ultimate dosing adjustments should be guided by itraconazole levels.</td>
</tr>
<tr>
<td></td>
<td>• Fluconazole 12 mg/kg body weight on day 1 and then 6–12 mg/kg body weight (maximum 600 mg) IV or by mouth once daily</td>
<td>• Itraconazole 5–10 mg/kg body weight by mouth given once daily, or 2.5–5 mg/kg body weight given twice daily (maximum 200 mg/dose) for a minimum of 8 weeks. A loading dose (2.5–5 mg/kg body weight per dose 3 times daily) is given for the first 3 days (maximum 200 mg/dose; 600 mg/day). See comment on itraconazole under Other Options/Issues.</td>
<td>Serum itraconazole concentrations should be monitored to optimize drug dosing. Amphotericin B may increase toxicity of flucytosine by increasing cellular uptake, or impair its renal excretion, or both. Flucytosine dose should be adjusted to keep 2-hour post-dose drug levels at 40–60 μg/mL. Oral acetazolamide should not be used for reduction of ICP in cryptococcal meningitis. Corticosteroids and mannitol have been shown to be ineffective in managing ICP in adults with cryptococcal meningitis. Secondary prophylaxis is recommended following completion of initial therapy (induction plus consolidation)—drugs and dosing listed above.</td>
</tr>
<tr>
<td></td>
<td><strong>Disseminated Disease (CNS Not Involved) or Severe Pulmonary Disease:</strong></td>
<td><strong>Localized Disease Including Isolated Pulmonary Disease (CNS Not Involved):</strong></td>
<td>Liposomal amphotericin and amphotericin B lipid complex are especially useful for children with renal insufficiency or infusion-related toxicity to amphotericin B deoxycholate. Liposomal amphotericin and amphotericin B lipid complex are significantly more expensive than amphotericin B deoxycholate.</td>
</tr>
<tr>
<td></td>
<td>• Amphotericin B 0.7–1.0 mg/kg body weight, or</td>
<td>• Amphotericin B 0.7–1.0 mg/kg body weight, or</td>
<td>Liquid preparation of itraconazole (if tolerated) is preferable to tablet formulation because of better bioavailability, but it is more expensive. Bioavailability of the solution is better than the capsule, but there were no upfront differences in dosing range based on preparation used. Ultimate dosing adjustments should be guided by itraconazole levels. Serum itraconazole concentrations should be monitored to optimize drug dosing. Amphotericin B may increase toxicity of flucytosine by increasing cellular uptake, or impair its renal excretion, or both. Flucytosine dose should be adjusted to keep 2-hour post-dose drug levels at 40–60 μg/mL. Oral acetazolamide should not be used for reduction of ICP in cryptococcal meningitis. Corticosteroids and mannitol have been shown to be ineffective in managing ICP in adults with cryptococcal meningitis. Secondary prophylaxis is recommended following completion of initial therapy (induction plus consolidation)—drugs and dosing listed above.</td>
</tr>
<tr>
<td></td>
<td>• Liposomal amphotericin, 3–5 mg/kg body weight, or</td>
<td>• Amphotericin liposomal 3–5 mg/kg body weight, or</td>
<td>Liposomal amphotericin and amphotericin B lipid complex are especially useful for children with renal insufficiency or infusion-related toxicity to amphotericin B deoxycholate. Liposomal amphotericin and amphotericin B lipid complex are significantly more expensive than amphotericin B deoxycholate.</td>
</tr>
<tr>
<td></td>
<td>• Amphotericin B lipid complex 5 mg/kg body weight IV once daily (± flucytosine)</td>
<td>• Amphotericin lipid complex, 5 mg/kg body weight IV once daily</td>
<td>Liquid preparation of itraconazole (if tolerated) is preferable to tablet formulation because of better bioavailability, but it is more expensive. Bioavailability of the solution is better than the capsule, but there were no upfront differences in dosing range based on preparation used. Ultimate dosing adjustments should be guided by itraconazole levels. Serum itraconazole concentrations should be monitored to optimize drug dosing. Amphotericin B may increase toxicity of flucytosine by increasing cellular uptake, or impair its renal excretion, or both. Flucytosine dose should be adjusted to keep 2-hour post-dose drug levels at 40–60 μg/mL. Oral acetazolamide should not be used for reduction of ICP in cryptococcal meningitis. Corticosteroids and mannitol have been shown to be ineffective in managing ICP in adults with cryptococcal meningitis. Secondary prophylaxis is recommended following completion of initial therapy (induction plus consolidation)—drugs and dosing listed above.</td>
</tr>
</tbody>
</table>

Key to Acronyms: cART = combination antiretroviral therapy; CNS = central nervous system; CSF = cerebrospinal fluid; ICP = intracranial pressure; IV = intravenous
# Cryptosporidiosis
(Last updated November 6, 2013; last reviewed November 6, 2013)

## Dosing Recommendations for Prevention and Treatment of Cryptosporidiosis

<table>
<thead>
<tr>
<th>Preventive Regimen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Primary Prophylaxis</strong></td>
<td>ARV therapy to avoid advanced immune deficiency</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td><strong>Secondary Prophylaxis</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
|                     | **Treatment**        | Effective cART:                                  | There is no consistently effective therapy for cryptosporidiosis in HIV-infected individuals; optimized cART and a trial of nitazoxanide can be considered. Nitazoxanide (BI, HIV-Uninfected; BII*, HIV-Infected in Combination with Effective cART):  
• 1–3 years: Nitazoxanide (20 mg/mL oral solution) 100 mg orally twice daily with food  
• 4–11 years: Nitazoxanide (20 mg/mL oral solution) 200 mg orally twice daily with food  
• ≥12 years: Nitazoxanide tablet 500 mg orally twice daily with food  
*Treatment duration:*  
• 3–14 days | Supportive Care:  
• Hydration, correct electrolyte abnormalities, nutritional support  
Antimotility agents (such as loperamide) should be used with caution in young children. |

**Key to Acronyms:** ARV = antiretroviral; cART = combination antiretroviral therapy
## Dosing Recommendations for Preventing and Treating CMV

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| **Primary Prophylaxis** | • For older children who can receive adult dose (based on their BSA), valganciclovir tablets 900 mg orally once daily with food | N/A         | Primary Prophylaxis Can Be Considered for:  
CMV antibody positivity and severe immunosuppression (i.e., CD4 cell count <50 cells/mm³ in children ≥6 years; CD4 percentage <5% in children <6 years)  
Criteria for Discontinuing Primary Prophylaxis:  
CD4 cell count >100 cells/mm³ for children ≥6 years; CD4 percentage >10% in children <6 years  
Criteria for Considering Restarting Primary Prophylaxis:  
CD4 cell count <50 cells/mm³ in children ≥6 years; CD4 percentage <5% in children <6 years |
|                     | • For children aged 4 months–16 years, valganciclovir oral solution 50 mg/mL at dose in milligrams = 7 x BSA x CrCl (up to maximum CrCl of 150 mL/min/1.73 m²) orally once daily with food (maximum dose 900 mg/day) |             |                                                                                       |
| **Secondary Prophylaxis** | • Ganciclovir 5 mg/kg body weight IV once daily, or  
• For older children who can receive adult dose (based on their BSA), valganciclovir tablets 900 mg orally once daily with food, or  
• For children age 4 months–16 years, valganciclovir oral solution 50 mg/mL (at dose in milligrams = 7 x BSA x CrCl up to maximum CrCl of 150 mL/min/1.73 m²) orally once daily with food, or  
• Foscarnet 90–120 mg/kg body weight IV once daily | • Cidofovir 5 mg/kg body weight per dose IV every other week. Must be given with probenecid and IV hydration. | Secondary Prophylaxis Indicated For:  
Prior disseminated disease, retinitis, neurologic disease, or GI disease with relapse  
Criteria for Discontinuing Secondary Prophylaxis  
If All of the Following Criteria Are Fulfilled:  
• Completed ≥6 months of CART  
• Consultation with ophthalmologist (if retinitis)  
• Age <6 years with CD4 percentage ≥15% for ≥6 consecutive months  
• Age ≥6 years with CD4 cell count >100 cells/mm³ for ≥6 consecutive months  
• For retinitis, routine (i.e., every 3–6 months) ophthalmological follow-up is recommended for early detection of relapse or immune restoration uveitis.  
Criteria for Restarting Secondary Prophylaxis:  
• Age <6 years with CD4 percentage <15%  
• Age ≥6 years with CD4 cell count <100 cells/mm³ |
## Dosing Recommendations for Preventing and Treating CMV

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Symptomatic Congenital Infection with Neurologic Involvement:</td>
<td>Ganciclovir 6 mg/kg body weight per dose IV every 12 hours for 6 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disseminated Disease and Retinitis: Induction Therapy (Followed by Chronic Suppressive Therapy):</td>
<td>Ganciclovir 5 mg/kg body weight per dose IV every 12 hours for 14–21 days (may be increased to 7.5 mg/kg body weight per dose IV twice daily), then 5 mg/kg body weight once daily for 5–7 days per week for chronic suppression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Central Nervous System Disease (Followed by Chronic Suppressive Therapy; See Secondary Prophylaxis):</td>
<td>Ganciclovir 5 mg/kg body weight per dose IV every 12 hours PLUS foscarnet 60 mg/kg body weight per dose IV every 8 hours (or 90 mg/kg body weight per dose IV every 12 hours) continued until symptomatic improvement, followed by chronic suppression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disseminated Disease and Retinitis: Induction Therapy (Followed by Chronic Suppressive Therapy):</td>
<td>Foscarnet, 60 mg/kg body weight per dose IV every 8 hours or 90 mg/kg body weight per dose IV every 12 hours x 14 to 21 days, then 90–120 mg/kg body weight IV once daily for chronic suppression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternatives for Retinitis (Followed by Chronic Suppressive Therapy; See Secondary Prophylaxis):</td>
<td>Valganciclovir tablets 900 mg per dose orally twice daily for 14–21 days, followed by chronic suppressive therapy (see above). <strong>Note:</strong> This is an option in older children who can receive the adult dose (based on their BSA).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV ganciclovir plus IV foscarnet (at above induction doses) may be considered as initial induction therapy in children with sight-threatening disease or for treatment following failure/relapse on monotherapy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cidofovir is also used to treat CMV retinitis in adults intolerant to other therapies. Induction dosing in adults is 5 mg/kg body weight IV once weekly for 2 weeks, followed by chronic suppressive therapy (see secondary prophylaxis); however, data on dosing in children are unavailable. Must be given with probenecid and IV hydration</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Data on valganciclovir dosing in young children for treatment of retinitis are unavailable, but consideration can be given to transitioning from IV ganciclovir to oral valganciclovir after improvement of retinitis is noted.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intravitreal injections of ganciclovir, foscarnet, or cidofovir are used in adults for retinitis but are not practical for most children.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Combination ganciclovir and foscarnet is associated with substantial rates of adverse effects, and optimal treatment for neurologic disease in children is unknown, particularly if receiving optimized cART.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chronic suppressive therapy (secondary prophylaxis) is recommended in adults and children following initial therapy of disseminated disease, retinitis, neurologic disease, or GI disease with relapse.</td>
<td></td>
</tr>
</tbody>
</table>

**Key to Acronyms:** BSA = body surface area; cART = combined antiretroviral therapy; CD4 = CD4 T lymphocyte; CMV = cytomegalovirus; CrCl = creatinine clearance; GI = gastrointestinal; IV = intravenous

---

*Guidelines for the Prevention and Treatment of Opportunistic Infections In HIV-Exposed and HIV-Infected Children* 10

Giardiasis  *(Last updated November 6, 2013; last reviewed November 6, 2013)*

### Dosing Recommendations for Prevention and Treatment of Giardiasis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prophylaxis</td>
<td>cART to avoid advanced immunodeficiency</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Secondary Prophylaxis</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| Treatment                | • Tinidazole, 50 mg/kg by mouth, administered as 1 dose given with food (maximum 2 g). **Note:** Based on data from HIV-uninfected children  
  • Nitazoxanide. **Note:** Based on data from HIV-uninfected children  
  • 1–3 years: 100 mg by mouth every 12 hours with food for 3 days  
  • 4–11 years: 200 mg by mouth every 12 hours with food for 3 days  
  • ≥12 years: 500 mg by mouth every 12 hours with food for 3 days | Metronidazole 5 mg/kg by mouth every 8 hours for 5-7 days.  
  **Note:** Based on data from HIV-uninfected children | Tinidazole is approved in the United States for children aged ≥3 years. It is available in tablets that can be crushed.  
Metronidazole has high frequency of gastrointestinal side effects. A pediatric suspension of metronidazole is not commercially available but can be compounded from tablets. It is not FDA-approved for the treatment of giardiasis.  
Supportive Care:  
• Hydration  
• Correction of electrolyte abnormalities  
• Nutritional support  
Antimotility agents (e.g., loperamide) should be used with caution in young children. |

**Key to Abbreviations:** cART = combination antiretroviral therapy; FDA = U.S. Food and Drug Administration
### Hepatitis B Virus  (Last updated November 6, 2013; last reviewed November 6, 2013)

**Dosing Recommendations for Prevention and Treatment of HBV in HIV/HBV Coinfected Children**  

(page 1 of 2)

<table>
<thead>
<tr>
<th>Preventive Regimen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>• Hepatitis B vaccine</td>
<td>• Combination of hepatitis B immunoglobulin and hepatitis B vaccine for infants born to mothers with hepatitis B infection</td>
<td>Hepatitis B immunoglobulin following exposure</td>
<td>See Figures 1 and 2 for detailed vaccine recommendations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Primary Prophylaxis Indicated for:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• All individuals who are not HBV infected</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria for Discontinuing Primary Prophylaxis:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria for Restarting Primary Prophylaxis:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• N/A</td>
</tr>
<tr>
<td><strong>Secondary Prophylaxis</strong></td>
<td>Hepatitis A Vaccine</td>
<td>N/A</td>
<td></td>
<td><strong>Secondary Prophylaxis Indicated for:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Chronically HBV-infected individuals to prevent further liver injury</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria for Discontinuing Secondary Prophylaxis:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria for Restarting Secondary Prophylaxis:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• N/A</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Treatment of Only HBV Required (Child Does Not Require cART):</td>
<td></td>
<td></td>
<td><strong>Indications for Treatment Include:</strong></td>
</tr>
<tr>
<td></td>
<td>• IFN-α 3 million units/m² body surface area SQ 3 times a week for 1 week, followed by dose escalation to 6 million units/m² body surface area (max 10 million units/dose), to complete a 24-week course, or</td>
<td>• IFN-α 10 million units/m² body surface area SQ 3 times a week for 6 months (sometimes used for retreatment of failed lower-dose interferon therapy)</td>
<td></td>
<td>• Detectable serum HBV DNA, irrespective of HBeAg status, for &gt;6 months; and</td>
</tr>
<tr>
<td></td>
<td>• For children aged ≥12 years, adefovir 10 mg by mouth once daily for a minimum of 12 months (uncertain if risk of HIV resistance)</td>
<td>• Alternative for 3TC: FTC 6 mg/kg body weight (maximum 200 mg) once daily</td>
<td></td>
<td>• Persistent (&gt;6 months) elevation of serum transaminases (≥ twice the upper limit of normal); or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Evidence of chronic hepatitis on liver biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IFN-α is contraindicated in children with decompensated liver disease; significant cytopenias, severe renal, neuropsychiatric, or cardiac disorders; and autoimmune disease.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Choice of HBV treatment options for HIV/HBV-co-infected children depends upon whether concurrent HIV treatment is warranted.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3TC and FTC have similar activity (and have cross-resistance) and should not be given together. FTC is not FDA-approved for treatment of HBV.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tenofovir is approved for use in treatment of HIV</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Treatment of Both HIV And HBV Required (Child Not Already Receiving 3TC or FTC)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 3TC 4 mg/kg body weight (maximum 150 mg) per dose by mouth twice daily as part of a fully suppressive cART regimen</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Guidelines for the Prevention and Treatment of Opportunistic Infections In HIV-Exposed and HIV-Infected Children*  

Downloaded from [https://aidsinfo.nih.gov/guidelines](https://aidsinfo.nih.gov/guidelines) on 2/26/2019
## Dosing Recommendations for Prevention and Treatment of HBV in HIV/HBV Coinfected Children

### Preventive Regimen

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment</strong></td>
<td>• For children aged ≥2 years, include tenofovir as part of cART regimen with 3TC or FTC. For children aged ≥12, tenofovir dose is 300 mg once daily. For children aged &lt;12 year, and 8 mg/kg body weight per dose once daily (maximum dose 300 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment of Both HIV and HBV Required (Child Already Receiving cART Containing 3TC or FTC. Suggesting 3TC/FTC Resistance):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• For children aged ≥2 years, include tenofovir as part of cART regimen with 3TC or FTC. For children aged ≥12 years, tenofovir dose is 300 mg once daily. For children aged &lt;12 years, 8 mg/kg body weight per dose once daily (maximum dose 300 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• For children aged ≥12 years, add adefovir 10 mg by mouth once daily or entecavir 0.5 mg by mouth once daily in addition to cART regimen.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• For children aged &lt;12 years, give 6-month course of IFN-α as above in addition to cART regimen.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Key to Acronyms:
- 3TC = lamivudine
- CART = combined antiretroviral therapy
- CD4 = CD4 T lymphocyte
- FTC = emtricitabine
- HBeAg = hepatitis B antigen
- HBV = hepatitis B virus
- IFN-α = interferon alfa
- IRIS = immune reconstitution inflammatory syndrome
- SQ = subcutaneous
- tenofovir = tenofovir disoproxil fumarate

---

**Guidelines for the Prevention and Treatment of Opportunistic Infections In HIV-Exposed and HIV-Infected Children**

Downloaded from [https://aidsinfo.nih.gov/guidelines](https://aidsinfo.nih.gov/guidelines) on 2/26/2019
## Dosing Recommendations for Prevention and Treatment of Hepatitis C Virus (HCV)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prophylaxis</td>
<td>None</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Secondary Prophylaxis</td>
<td>None</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| Treatment                  | IFN-α Plus Ribavirin Combination Therapy:  
  - Pegylated IFN-α: Peg-IFN 2a  
    180 μg/1.73 m² body surface area subcutaneously once per week (maximum dose 180 μg) OR Peg-IFN 2b  
    60 μg/m² body surface area once per week  
  PLUS  
  - Ribavirin (oral) 7.5 mg/kg body weight twice daily (fixed dose by weight recommended):  
    - 25–36 kg: 200 mg a.m. and p.m.  
    - >36 to 49 kg: 200 mg a.m. and 400 mg p.m.  
    - >49 to 61 kg: 400 mg a.m. and p.m.  
    - >61 to 75 kg: 400 mg a.m. and 600 mg p.m.  
    - >75 kg: 600 mg a.m. and p.m.  
  Treatment Duration:  
  - 48 weeks, regardless of HCV genotype | None                          | Optimal duration of treatment for HIV/HCV-coinfected children is unknown and based on recommendations for HIV/HCV-coinfected adults  
  Treatment of HCV in children <3 years generally is not recommended.  
  Indications for treatment are based on recommendations in HIV/HCV-coinfected adults; because HCV therapy is more likely to be effective in younger patients and in those without advanced disease or immunodeficiency, treatment should be considered for all HIV/HCV-coinfected children aged >3 years in whom there are no contraindications to treatment  
  For recommendations related to use of telaprevir or boceprevir in adults, including warnings about drug interactions between HCV protease inhibitors and HIV protease inhibitors and other antiretroviral drugs, see [Adult OI guidelines](https://aidsinfo.nih.gov/guidelines).  
  IRIS may be manifested by dramatic increase in transaminases as CD4 cell counts rise within the first 6–12 weeks of cART. It may be difficult to distinguish between IRIS and drug-induced hepatotoxicity or other causes of hepatitis.  
  IFN-α is contraindicated in children with decompensated liver disease, significant cytopenias, renal failure, severe cardiac disorders and non-HCV-related autoimmune disease.  
  Ribavirin is contraindicated in children with unstable cardiopulmonary disease, severe pre-existing anemia or hemoglobinopathy.  
  Didanosine combined with ribavirin may lead to increased mitochondrial toxicities; concomitant use is contraindicated.  
  Ribavirin and zidovudine both are associated with anemia, and when possible, should not be administered together |
## Dosing Recommendations for Prevention and Treatment of Herpes Simplex Virus (HSV) Infections

### Indication

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prophylaxis</td>
<td>None.</td>
<td>None.</td>
<td>Primary prophylaxis is not indicated.</td>
</tr>
<tr>
<td>Secondary Prophylaxis</td>
<td><strong>Mucocutaneous Disease:</strong></td>
<td><strong>Mucocutaneous Disease, For Adolescents</strong></td>
<td>Secondary Prophylaxis Indicated:</td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 20 mg/kg body weight/dose (maximum 800 mg/dose) by mouth BID</td>
<td>• Valacyclovir 500 mg by mouth BID; or • Famciclovir 500 mg by mouth BID</td>
<td>• Suppressive secondary prophylaxis can be considered for children with severe and recurrent mucocutaneous (oral or genital) disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Criteria for Discontinuing Secondary Prophylaxis:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• After a prolonged period (e.g., 1 year) of prophylaxis, consider suspending prophylaxis and determine with the patient whether additional prophylaxis is necessary. Although level of immune reconstitution is a consideration, no specific CD4 threshold has been established.</td>
</tr>
<tr>
<td></td>
<td><strong>Suppressive Therapy After Neonatal Skin, Eye, Mouth, or CNS Disease:</strong></td>
<td></td>
<td>For Neonatal CNS Disease:</td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 300 mg/m² body surface area/dose by mouth TID for 6 months</td>
<td></td>
<td>• Repeat CSF HSV DNA PCR should be performed on days 19 to 21 of therapy; do not stop acyclovir until repeat CSF HSV DNA PCR is negative.</td>
</tr>
<tr>
<td>Treatment</td>
<td><strong>Neonatal CNS or Disseminated Disease:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 20 mg/kg body weight IV/dose TID for ≥21 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Neonatal Skin, Eye, or Mouth Disease:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 20 mg/kg body weight IV/dose TID for 14 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>CNS or Disseminated Disease in Children Outside the Neonatal Period:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 10 mg/kg body weight (up to 20 mg/kg body weight/dose in children &lt;12 years) IV TID for 21 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderate to Severe Symptomatic Gingivostomatitis:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 5–10 mg/kg body weight/dose IV TID. Patients can be switched to oral therapy after lesions have begun to regress and therapy continued until lesions have completely healed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mild Symptomatic Gingivostomatitis:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 20 mg/kg body weight (maximum 400 mg/dose) dose by mouth QID for 7–10 days</td>
<td>• Valacyclovir is approved for immunocompetent adults and adolescents with first-episode mucocutaneous HSV at a dose of 1 g/dose by mouth BID for 7–10 days; also approved for recurrent herpes labialis in children ≥12 years using two, 2 g doses by mouth separated by 12 hours as single-day therapy.</td>
<td></td>
</tr>
<tr>
<td>Indication</td>
<td>First Choice</td>
<td>Alternative</td>
<td>Comments/Special Issues</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Treatment, continued</td>
<td>Recurrent Herpes Labialis:</td>
<td>• Recurrent genital HSV can be treated with valacyclovir 500 mg BID for 3 days or 1 g by mouth daily for 5 days.</td>
<td>• There is no pediatric preparation of valacyclovir (although crushed capsules can be used to make a suspension) and data on dosing in children are limited; can be used by adolescents able to receive adult dosing.</td>
</tr>
<tr>
<td>For First-Episode Genital Herpes (Adults and Adolescents):</td>
<td>• Acyclovir 20 mg/kg body weight (maximum 400 mg/dose) dose by mouth QID for 5 days</td>
<td>• Immunocompetent adults with recurrent herpetic labialis can be treated with famciclovir, 1 g/dose by mouth BID for 1 day.</td>
<td>• There is no pediatric preparation of famciclovir and data on dosing in children are unavailable; can be used by adolescents able to receive adult dosing.</td>
</tr>
<tr>
<td>Recurrent Genital Herpes (Adults and Adolescents):</td>
<td>• Acyclovir 20 mg/kg body weight (maximum 400 mg/dose) dose by mouth TID for 7–10 days</td>
<td>• Famciclovir is approved to treat primary genital HSV in immunocompetent adults at a dose of 250 mg/dose by mouth TID for 7–10 days.</td>
<td>• Famciclovir is approved for use in HIV-infected adults and adolescents with recurrent mucocutaneous HSV infection at a dose of 500 mg/dose by mouth BID for 7 days.</td>
</tr>
<tr>
<td>Children with HSV Keratoconjunctivitis:</td>
<td>• Often treated with topical trifluridine (1%) or acyclovir (3%) applied as 1–2 drops 5 times daily. Many experts add oral acyclovir to the topical therapy.</td>
<td>• Acyclovir is approved for use in HIV-infected adults and adolescents with recurrent mucocutaneous HSV infection at a dose of 500 mg/dose by mouth BID for 7 days.</td>
<td>• Acyclovir-Resistant HSV Infection:</td>
</tr>
<tr>
<td>Children with ARN:</td>
<td>• For children old enough to receive adult dose, acyclovir 10–15 mg/kg body weight/dose IV every 8 hours for 10–14 days, followed by oral valacyclovir 1 g/dose TID for 4–6 weeks</td>
<td>• Foscarnet 40 mg/kg body weight/dose given IV TID (or 60 mg/kg body weight/dose BID) should be administered slowly over the course of 2 hours (i.e., no faster than 1 mg/kg/minute).</td>
<td>• Alternative and Short-Course Therapy in Immunocompromised Adults with Recurrent Genital Herpes:</td>
</tr>
<tr>
<td></td>
<td>• As an alternative, oral acyclovir 20 mg/kg body weight/dose QID for 4–6 weeks after IV acyclovir for 10–14 days</td>
<td>• Acyclovir 800 mg per dose by mouth BID for 5 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Acyclovir 800 mg per dose by mouth TID for 2 days</td>
<td></td>
</tr>
</tbody>
</table>

Note: Consultation with an ophthalmologist experienced in managing herpes simplex infection involving the eye and its complications in children is strongly recommended when ocular disease is present.

Key to Acronyms: ARN = acute retinal necrosis; BID = twice daily; CD4 = CD4 T lymphocyte; CNS = central nervous system; CSF = cerebrospinal fluid; HSV = herpes simplex virus; IV = intravenous; PCR = polymerase chain reaction; QID = four times daily; TID = three times daily
### Histoplasmosis (Last updated November 6, 2013; last reviewed November 6, 2013)

**Dosing Recommendations for Preventing and Treating Histoplasmosis (page 1 of 2)**

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>Primary Prophylaxis indicated for selected HIV-infected adults but not children.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria for Discontinuing Primary Prophylaxis:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria for Restarting Primary Prophylaxis:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• N/A</td>
</tr>
<tr>
<td><strong>Secondary Prophylaxis</strong> (Suppressive Therapy)</td>
<td>Itraconazole oral solution 5–10 mg/kg body weight (maximum 200 mg) per dose by mouth daily</td>
<td>Fluconazole 3–6 mg/kg body weight (maximum 200 mg) by mouth once daily</td>
<td><strong>Secondary Prophylaxis Indicated:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Documented histoplasmosis in a patient with impaired immune function</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Criteria For Discontinuing Secondary Prophylaxis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If All of the Following Criteria Are Fulfilled:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• CD4 percentage &gt;15% at any age; or CD4 cell count &gt;150 cells/mm³ aged ≥6 years.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Received ≥1 year itraconazole maintenance therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Established (e.g., ≥6 months) adherence to effective cART</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Negative Histoplasma blood cultures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Serum Histoplasma antigen &lt;2 ng/mL</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td><strong>Acute Primary Pulmonary Histoplasmosis:</strong></td>
<td></td>
<td>Use same initial itraconazole dosing for capsules as for solution. Itraconazole solution is preferred to the capsule formulation because it is better absorbed; solution can achieve serum concentrations 30% higher than those achieved with the capsules.</td>
</tr>
<tr>
<td></td>
<td>• Itraconazole oral solution loading dose of 2–5 mg/kg body weight (maximum 200 mg) per dose by mouth 3 times daily for first 3 days of therapy, followed by 2–5 mg/kg body weight (max 200 mg) per dose by mouth twice daily for 12 months. Duration of 12 weeks is sufficient for HIV-infected children, with functional cellular immunity (CD4 percentage &gt;20% or if aged ≥6, CD4 cell count &gt;300 cells/mm³), provided monitoring confirms clinical improvement and decreased urine antigen concentrations.</td>
<td><strong>Mild Disseminated Disease:</strong></td>
<td>Use same initial itraconazole dosing for capsules as for solution. Itraconazole solution is preferred to the capsule formulation because it is better absorbed; solution can achieve serum concentrations 30% higher than those achieved with the capsules.</td>
</tr>
<tr>
<td></td>
<td>• Fluconazole 3–6 mg/kg body weight (maximum 200 mg) by mouth once daily</td>
<td><strong>Mild Disseminated Disease:</strong></td>
<td>Urine antigen concentration should be assessed at diagnosis. If &gt;39 ng/mL, serum concentrations should be followed. When serum levels become undetectable, urine concentrations should be monitored monthly during treatment and followed thereafter to identify relapse. Serum concentrations of itraconazole should be monitored and achieve a level of 1 μg/mL at steady-state. Levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Serum concentrations of itraconazole should be monitored and achieve a level of 1 μg/mL at steady-state. Levels</td>
</tr>
</tbody>
</table>
### Indication

<table>
<thead>
<tr>
<th>Treatment, continued</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>first 3 days of therapy, followed by 2–5 mg/kg body weight (maximum 200 mg) per dose by mouth twice daily for 12 months</td>
<td>mg) per dose, twice daily (maximum 600 mg/day) for 12 months</td>
<td>exceeding 10 µg/mL should be followed by dose reduction.</td>
</tr>
<tr>
<td></td>
<td><strong>Moderately Severe to Severe Disseminated Disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Acute Therapy (Minimum 2-Week Induction, Longer if Clinical Improvement is Delayed, Followed by Consolidation Therapy):</strong></td>
<td></td>
<td>High relapse rate with CNS infection occurs in adults and longer therapy may be required; treatment in children is anecdotal and expert consultation should be considered.</td>
</tr>
<tr>
<td></td>
<td>• Liposomal amphotericin B 3–5 mg/kg body weight, IV once daily (preferred)</td>
<td><strong>Moderately Severe to Severe Disseminated Disease:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Amphotericin B deoxycholate 0.7–1 mg/kg body weight IV once daily (alternative)</td>
<td>• If itraconazole not tolerated, amphotericin alone for 4–6 weeks can be used with monitoring that confirms decline in histoplasma urine and serum antigen levels.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Consolidation Therapy (Followed by Chronic Suppressive Therapy):</strong></td>
<td>• Liposomal amphotericin B 3–5 mg/kg body weight IV once daily (preferred) for 4–6 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Itraconazole oral solution initial loading dose of 2–5 mg/kg body weight (maximum 200 mg) per dose by mouth 3 times daily for first 3 days of therapy, followed by 2–5 mg/kg body weight (max 200 mg) per dose by mouth given twice daily for 12 months</td>
<td>• Amphotericin B deoxycholate 0.7–1 mg/kg body weight IV once daily (alternative) for 4–6 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Central Nervous System Infection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Acute Therapy (4–6 Weeks, Followed by Consolidation Therapy):</strong></td>
<td></td>
<td>High relapse rate with CNS infection occurs in adults and longer therapy may be required; treatment in children is anecdotal and expert consultation should be considered.</td>
</tr>
<tr>
<td></td>
<td>• Liposomal amphotericin B, 5 mg/kg body weight IV once daily (AII)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Consolidation Therapy (Followed by Chronic Suppressive Therapy):</strong></td>
<td></td>
<td>Chronic suppressive therapy (secondary prophylaxis) with itraconazole is recommended in adults and children following initial therapy.</td>
</tr>
<tr>
<td></td>
<td>• Itraconazole oral solution initial loading dose of 2–5 mg/kg body weight (maximum 200 mg) per dose by mouth 3 times daily for first 3 days of therapy, followed by 2–5 mg/kg body weight (max 200 mg) per dose by mouth given twice daily for ≥12 months and until histoplasma antigen is no longer detected in cerebrospinal fluid</td>
<td>• Amphotericin B deoxycholate is better tolerated in children than in adults. Liposomal amphotericin B is preferred for treatment of parenchymal cerebral lesions.</td>
<td></td>
</tr>
</tbody>
</table>

**Key to Acronyms:** cART = combination antiretroviral therapy; CD4 = CD4 T lymphocyte; CNS = central nervous system; IV = intravenous
Human Papillomavirus (HPV) (Last updated November 6, 2013; last reviewed November 6, 2013)

### Dosing Recommendations for Prevention and Treatment of Human Papillomavirus (HPV)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prophylaxis</td>
<td>HPV vaccine</td>
<td>N/A</td>
<td>See Figure 2 for detailed vaccine recommendations.</td>
</tr>
<tr>
<td>Secondary Prophylaxis</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td><strong>Podofilox solution/gel (0.5%) applied topically BID for 3 consecutive days a week up to 4 weeks (patient applied). Withhold treatment for 4 days and repeat the cycle weekly up to 4 times (BII)</strong></td>
<td><strong>Intralesional IFN-α is generally not recommended because of high cost, difficult administration, and potential for systemic side effects (CIII)</strong></td>
<td>Adequate topical anesthetics to the genital area should be given before caustic modalities are applied. Sexual contact should be limited while solutions or creams are on the skin. Although sinecatechins (15% ointment) applied TID up to 16 weeks is recommended in immunocompetent individuals, data are insufficient on safety and efficacy in HIV-infected individuals. cART has not been consistently associated with reduced risk of HPV-related cervical abnormalities in HIV-infected women. Laryngeal papillomatosis generally requires referral to a pediatric otolaryngologist. Treatment is directed at maintaining the airway, rather than removing all disease. For women who have exophytic cervical warts, a biopsy to exclude HSIL must be performed before treatment. Liquid nitrogen or TCA/BCA is recommended for vaginal warts. Use of a cryoprobe in the vagina is not recommended. Cryotherapy with liquid nitrogen or podophyllin resin (10%–25%) is recommended for urethral meatal warts. Cryotherapy with liquid nitrogen or TCA/BCA or surgical removal is recommended for anal warts. Abnormal Pap smear cytology should be referred to colposcopy for diagnosis and management.</td>
</tr>
<tr>
<td></td>
<td><strong>Imiquimod cream (5%) applied topically at night and washed off in the morning for 3 non-consecutive nights a week for up to 16 weeks (patient applied) (BII)</strong></td>
<td><strong>Cidofovir topical gel (1%) is an experimental therapy studied in HIV-infected adults that is commercially available through compounding pharmacies and has very limited use in children; systemic absorption can occur (CIII).</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TCA or BCA (80%–90%) applied topically weekly for up to 3 to 6 weeks (provider applied) (BII)</strong></td>
<td><strong>5-FU/epinephrine gel implant should be offered in only severe recalcitrant cases because of inconvenient routes of administration, frequent office visits, and a high frequency of systemic adverse effects.</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Podophyllin resin (10%–25% suspension in tincture of benzoin) applied topically and washed off several hours later, repeated weekly for 3 to 6 weeks (provider applied) (CIII)</strong></td>
<td><strong>Cryotherapy with liquid nitrogen or podophyllin resin (10%–25%) is recommended for urethral meatal warts.</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Cryotherapy with liquid nitrogen or cryoprobe applied every 1–2 weeks (BII)</strong></td>
<td><strong>Cryotherapy with liquid nitrogen or TCA/BCA or surgical removal is recommended for anal warts.</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Surgical removal either by tangential excision, tangential shave excision, curettage, or electrocautery</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key to Acronyms:** 5-FU = 5-fluorouracil; BCA = bichloroacetic acid; BID = twice daily; cART = combination antiretroviral therapy; HPV = human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; IFN-α = interferon alfa; TCA = trichloroacetic acid; TID = three times daily
## Dosing Recommendations for Chemoprophylaxis and Treatment of Influenza

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Chemoprophylaxis</strong></td>
<td>Oseltamivir</td>
<td>None</td>
<td><strong>Pre-Exposure Chemoprophylaxis</strong></td>
</tr>
<tr>
<td>(Pre- and Post-Exposure)</td>
<td></td>
<td></td>
<td><strong>Indications:</strong></td>
</tr>
<tr>
<td><strong>Influenza A and B</strong></td>
<td></td>
<td></td>
<td>• After careful consideration of risks and benefits, pre-exposure antiviral chemoprophylaxis may be considered for children with HIV with severe immunosuppression while influenza virus is circulating in the community.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Duration:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• When employed, pre-exposure antiviral chemoprophylaxis should continue for the duration of influenza virus circulation in the community.</td>
</tr>
<tr>
<td><strong>Indications Recommended For:</strong></td>
<td></td>
<td></td>
<td><strong>Post-Exposure Chemoprophylaxis</strong></td>
</tr>
<tr>
<td><strong>Children with HIV with severe immunosuppression regardless of influenza vaccination status.</strong></td>
<td></td>
<td></td>
<td><strong>Indications Recommended For:</strong></td>
</tr>
<tr>
<td><strong>Children with HIV with moderate to no immunosuppression if</strong></td>
<td></td>
<td></td>
<td>• Influenza vaccination is contraindicated or unavailable; or</td>
</tr>
<tr>
<td>• Influenza vaccination is contraindicated or unavailable; or</td>
<td></td>
<td></td>
<td>• Low influenza vaccine effectiveness is documented in the current influenza season; and</td>
</tr>
<tr>
<td><strong>Antiviral chemoprophylaxis can be started within 48 hours of exposure to an ill person with confirmed or suspected influenza.</strong></td>
<td></td>
<td></td>
<td>• Antiviral chemoprophylaxis can be started within 48 hours of exposure to an ill person with confirmed or suspected influenza.</td>
</tr>
<tr>
<td><strong>Duration:</strong></td>
<td></td>
<td></td>
<td><strong>Note:</strong> Duration of chemoprophylaxis depends on the type of exposure, whether influenza vaccination was provided after the exposure, and whether influenza vaccine is anticipated to be effective based on the child’s degree of immunosuppression and the degree of match with circulating influenza viruses.</td>
</tr>
<tr>
<td>* If influenza vaccination is provided after contact, chemoprophylaxis duration should be 2 weeks after vaccination.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* If exposure is to a household contact, chemoprophylaxis duration should be 7 days.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* If chemoprophylaxis is provided in setting of an institutional outbreak, the duration is either 14 days or 7 days after onset of symptoms in the last person infected, whichever is longer.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oseltamivir Dosing Adjustments</strong></td>
<td></td>
<td></td>
<td><strong>Premature Infants:</strong></td>
</tr>
<tr>
<td><strong>Renal Insufficiency:</strong></td>
<td></td>
<td></td>
<td>• Current weight-based dosing recommendations for oseltamivir are not appropriate for premature infants (i.e., gestational age at delivery &lt;38 weeks).</td>
</tr>
<tr>
<td><strong>Renal Insufficiency:</strong></td>
<td></td>
<td></td>
<td><strong>Renal Insufficiency:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• A reduction in dose of oseltamivir is recommended for patients with CrCl &lt;30 mL/min. For patients with CrCl 10–30 mL/min, a reduction in chemoprophylaxis dosing frequency to every other day is recommended. Pharmacokinetic data are limited for dosing recommendations for patients with severe renal insufficiency on dialysis.</td>
</tr>
</tbody>
</table>
Dosing Recommendations for Chemoprophylaxis and Treatment of Influenza

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary Chemoprophylaxis</td>
<td>N/A</td>
<td>N/A</td>
<td>No role for secondary chemoprophylaxis</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza A and B</td>
<td>Oseltamivir&lt;sup&gt;a&lt;/sup&gt;</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged &lt;3 Months: Oseltamivir 3 mg/kg/dose twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged 3 Months to &lt;1 Year: Oseltamivir 3 mg/kg/dose twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged ≥1 to 12 Years: Weight-band dosing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weighing ≤15 kg: Oseltamivir 30 mg twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weighing &gt;15 kg to 23 kg: Oseltamivir 45 mg twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weighing &gt;23 kg to 40 kg: Oseltamivir 60 mg twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weighing &gt;40 kg: Oseltamivir 75 mg twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aged ≥13 Years: Oseltamivir 75 mg twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zanamivir (Aged ≥7 Years):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Zanamivir 10 mg (2 inhalations) twice daily&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Oseltamivir is FDA-approved for prophylaxis of influenza in children aged ≥1 year. It is not approved for prophylaxis in children aged <1 year. However, CDC recommends that health care providers who treat children aged ≥3 months to <1 year administer a chemoprophylaxis dose of oseltamivir 3 mg/kg body weight/dose once daily. Chemoprophylaxis for infants aged <3 months is not recommended unless the exposure situation is judged to be critical.

<sup>b</sup> Zanamivir is not recommended for chemoprophylaxis in children aged <5 years or for children with underlying respiratory disease.

<sup>c</sup> See Fiore 2011 and Influenza Antiviral Medications: Summary for Clinicians for further details.


<sup>e</sup> Oseltamivir is FDA-approved for treatment of influenza in children aged ≥2 weeks; however, both CDC and AAP recommend use of oral oseltamivir for influenza treatment in infants aged <2 weeks.

<sup>f</sup> Zanamivir is not recommended for treatment in children aged <7 years or for children with underlying respiratory disease.

**Key to Acronyms:** AAP = American Academy of Pediatrics; CDC = Centers for Disease Control and Prevention; CrCl = creatinine clearance; ESRD = end stage renal disease; FDA = Food and Drug Administration; PK = pharmacokinetic
## Dosing Recommendations for Prevention and Treatment of Isosporiasis (Cystoisosporiasis)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prophylaxis</td>
<td>There are no U.S. recommendations for primary prophylaxis of isosporiasis.</td>
<td>N/A</td>
<td>Initiation of cART to avoid advanced immunodeficiency may reduce incidence; TMP-SMX prophylaxis may reduce incidence.</td>
</tr>
</tbody>
</table>
| Secondary Prophylaxis    | If Severe Immunosuppression:  
  • Administer TMP-SMX 2.5 mg/kg body weight of TMP component twice daily by mouth 3 times per week | Pyrimethamine 1 mg/kg body weight (maximum 25 mg) plus folic acid, 10–25 mg by mouth once daily.  
  **Second-Line Alternative:**  
  • Ciprofloxacin, 10–20 mg/kg body weight given twice daily by mouth 3 times per week | Consider discontinuing secondary prophylaxis in a patient receiving cART after sustained improvement from severe immunosuppression (from CDC immunologic category 3 to CD4 values that fall within category 1 or 2) for longer than 6 months. |
| Treatment                | TMP-SMX 5 mg/kg body weight of TMP component given twice daily by mouth for 10 days | Pyrimethamine 1 mg/kg body weight plus folic acid 10-25 mg by mouth once daily for 14 days  
  **Second-Line Alternatives:**  
  • Ciprofloxacin 10–20 mg/kg body weight/day twice daily by mouth for 7 days  
  • Nitazoxanide (see doses below) for 3 consecutive days  
  • Children 1–3 years: 100 mg by mouth every 12 hours  
  • Children 4–11 years: 200 mg by mouth every 12 hours  
  • Adolescents ≥12 years and adults: 500 mg by mouth every 12 hours | If symptoms worsen or persist, the TMP-SMX dose may be increased to 5 mg/kg/day given 3–4 times daily by mouth for 10 days or the duration of treatment may be lengthened. Duration of treatment with pyrimethamine has not been well established.  
  Ciprofloxacin is generally not a drug of first choice in children due to increased incidence of adverse events, including events related to joints and/or surrounding tissues. |

**Key to Acronyms:** CD4 = CD4 T lymphocyte; CDC = Centers for Disease Control and Prevention; cART = combination antiretroviral therapy; TMP-SMX = trimethoprim-sulfamethoxazole
Malaria (Last updated November 6, 2013; last reviewed November 6, 2013)

Dosing Recommendations for Prevention and Treatment of Malaria (page 1 of 3)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>For Travel To Chloroquine-Sensitive Areas:</td>
<td>Recommendations are the same for HIV-infected and HIV-uninfected children. Please refer to the following website for the most recent recommendations based on region and drug susceptibility: <a href="http://www.cdc.gov/malaria/">http://www.cdc.gov/malaria/</a>.</td>
</tr>
<tr>
<td></td>
<td>• Chloroquine base 5 mg/kg body weight base by mouth, up to 300 mg once weekly (equivalent to 7.5 mg/kg body weight chloroquine phosphate). Start 1–2 weeks before leaving, take weekly while away, and then take once weekly for 4 weeks after returning home</td>
<td>For travel to chloroquine-sensitive areas. Equally recommended options include chloroquine, atovaquone/proguanil, doxycycline (for children aged ≥8 years), and mefloquine; primaquine is recommended for areas with mainly <em>P. vivax</em>. G6PD screening must be performed prior to primaquine use. Chloroquine phosphate is the only formulation of chloroquine available in the United States; 10 mg of chloroquine phosphate = 6 mg of chloroquine base.</td>
</tr>
<tr>
<td></td>
<td>• Atovaquone/proguanil once daily started 1–2 days before travel, for duration of stay, and then for 1 week after returning home</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 11–20 kg; 1 pediatric tablet (62.5 mg/25 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 21–30 kg, 2 pediatric tablets (125 mg/50 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 31–40 kg, 3 pediatric tablets (187.5 mg/75 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• &gt;40 kg; 1 adult tablet (250 mg/100 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 2.2 mg/kg body weight (maximum 100 mg) by mouth once daily for children aged ≥8 years. Must be taken 1–2 days before travel, daily while away, and then up to 4 weeks after returning</td>
<td>For travel to chloroquine-resistant areas, preferred drugs are atovaquone/proguanil, doxycycline (for children aged ≥8 years) or mefloquine.</td>
</tr>
<tr>
<td></td>
<td>• Mefloquine 5 mg/kg body weight orally given once weekly (max 250 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>For Areas with Mainly <em>P. Vivax</em>:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Primaquine phosphate 0.6 mg/kg body weight base once daily by mouth, up to a maximum of 30 mg base/day. Starting 1 day before leaving, taken daily, and for 3–7 days after return</td>
<td></td>
</tr>
<tr>
<td></td>
<td>For Travel to Chloroquine-Resistant Areas:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Atovaquone/proguanil once daily started 1–2 days before travel, for duration of stay, and then for 1 week after returning home</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 11–20 kg; 1 pediatric tablet (62.5 mg/25 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 21–30 kg, 2 pediatric tablets (125 mg/50 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 31–40 kg, 3 pediatric tablets (187.5 mg/75 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• &gt;40 kg; 1 adult tablet (250 mg/100 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 2.2 mg/kg body weight (maximum 100 mg) by mouth once daily for children aged ≥8 years. Must be taken 1–2 days before travel, daily while away, and then up to 4 weeks after returning</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mefloquine 5 mg/kg body weight orally given once weekly (maximum 250 mg)</td>
<td></td>
</tr>
</tbody>
</table>
### Indication | First Choice | Comments/Special Issues
--- | --- | ---
**Secondary Prophylaxis**<br>For *P. vivax* or *P. ovale*:<br>• Primaquine 0.5 mg/kg base (0.8 mg/kg salt) up to adult dose orally, dailily for 14 days after departure from the malarious area<br>This regimen, known as PART, is recommended only for individuals who have resided in a malaria-endemic area for an extended period of time. Adult dose: 30 mg base (52.6 mg salt) orally, daily for 14 days after departure from the malarious area.<br><http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/malaria.htm#1939

**Treatment**<br>Uncomplicated *P. Falciparum* or Unknown Malaria Species (All Malaria Areas Except Those Listed as Chloroquine Sensitive) or Unknown Region:<br>• Atovaquone-proguanil (pediatric tablets 62.5 mg/25 mg; adult tablets 250 mg/100 mg), dosed once daily:<br>• 5–8 kg; 2 pediatric tablets for 3 days;<br>• 9–10 kg; 3 pediatric tablets for 3 days;<br>• 11–20 kg; 4 pediatric tablets or 1 adult tablet for 3 days;<br>• 21–30 kg; 2 adult tablets for 3 days;<br>• 31–40 kg; 3 adult tablets for 3 days;<br>• >40 kg; 4 adult tablets for 3 days
For quine-based regimens, doxycycline or tetracycline should be used only in children aged ≥8 years. An alternative for children aged ≥8 years is clindamycin 7 mg/kg body weight per dose by mouth given every 8 hours. Clindamycin should be used for children aged <8 years.
Before primaquine is given, G6PD status must be verified.
Primaquine may be given in combination with chloroquine if the G6PD status is known and negative, otherwise give after chloroquine (when G6PD status is available)
For most updated prevention and treatment recommendations for specific region, refer to updated CDC treatment table available at <http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf

Uncomplicated *P. Falciparum* OR Unknown Malaria Species From Chloroquine-Sensitive Region (See Comments for Link to Resistance Map):<br>• Chloroquine phosphate: 16.6 mg/kg body weight (10 mg/kg body weight chloroquine base) (maximum 1000 mg) by mouth once, then 8.3 mg/kg body weight (maximum 500 mg) by mouth at 6, 24, and 48 hours (total dose = 41.6 mg/kg body weight chloroquine phosphate [maximum 2500 mg] = 25 mg/kg body weight chloroquine base)

*P. vivax*, *P. ovale*, *P. malariae*, *P. knowlesi* (All Areas Except Papua New Guinea, Indonesia; See Comments)<br>Initial Therapy (Followed by Anti-Relapse Therapy for *P. Ovale* and *P. Vivax*):<br>• Chloroquine phosphate 16.6 mg/kg body weight (10 mg/kg body weight chloroquine base) (maximum 1000 mg) by mouth once, then 8.3 mg/kg body weight (maximum 500 mg) by mouth at 6, 24, and 48 hours (total dose = 41.6 mg/kg body weight chloroquine phosphate [maximum 2500 mg] = 25 mg/kg body weight chloroquine base)

Anti-Relapse Therapy for *P. ovale*, *P. vivax*:<br>• Primaquine 0.5 mg base/kg body weight (max 30 mg base) by mouth once daily for 14 days
For sensitive and resistant malaria map: <http://cdc-malaria.ncsa.uiuc.edu/

High treatment failure rates due to chloroquine-resistant *P. vivax* have been documented in Papua New Guinea and Indonesia. Treatment should be selected from one of the three following options:<br>• Atovaquone-proguanil plus primaquine phosphate<br>• Quinine sulfate plus EITHER doxycycline OR tetracycline PLUS primaquine phosphate. This regimen cannot be used in children aged <8 years.<br>• Mefloquine plus primaquine phosphate
<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment, continued</td>
<td><strong>Uncomplicated <em>P. falciparum</em> or Unknown Malaria Species from Chloroquine-Resistant Areas (All Malaria Areas Except Those Listed as Chloroquine Sensitive) or Unknown Region:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mefloquine (250-mg tablets only): 15 mg/kg body weight (maximum 750 mg) by mouth once, then 10 mg/kg body weight (maximum 500 mg) by mouth given 12 hours later</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Quinine sulfate 10 mg/kg body weight (maximum 650 mg) per dose by mouth every 8 hours for 3 to 7 days, <strong>plus</strong> Clindamycin 7 mg/kg body weight per dose by mouth every 8 hours for 7 days, <strong>or</strong> doxycycline: 2.2 mg/kg body weight per dose (maximum 100 mg) given by mouth every 12 hours, <strong>or</strong> tetracycline 6–12.5 mg/kg body weight per dose by mouth given every 6 hours (maximum dose: 500 mg per dose given 4 times daily) for 7 days.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Artemether-lumefantrine: 1 tablet = 20 mg Artemether and 120 mg lumefantrine, a 3-day treatment schedule for a total of 6 doses. The second dose follows the initial dose 8 hours later, then 1 dose twice daily for the next 2 days.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 5 to &lt;15 kg; 1 tablet per dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 15 to &lt;25 kg; 2 tablets per dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 25 to &lt;35 kg; 3 tablets per dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• &gt;35 kg; 4 tablets per dose</td>
<td></td>
</tr>
<tr>
<td>Severe Malaria</td>
<td><strong>Quinidine gluconate 10 mg/kg body weight IV loading dose over 1–2 hours, then 0.02 mg/kg body weight/minute infusion for ≥24 hours (Treatment duration: 7 days in Southeast Asia, Oceania, otherwise 3 days)</strong></td>
<td><strong>Quinidine gluconate is a class 1a anti-arrhythmic agent not typically stacked in pediatric hospitals. When regional supplies are unavailable, the CDC Malaria hotline may be of assistance (see below). <strong>Do not</strong> give quinidine gluconate as an IV bolus. Quinidine gluconate IV should be administered in a monitored setting. Cardiac monitoring required. Adverse events including severe hypoglycemia, prolongation of the QT interval, ventricular arrhythmia, and hypotension can result from the use of this drug at treatment doses.</strong></td>
</tr>
<tr>
<td></td>
<td><strong>PLUS One of the Following:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Doxycycline 100 mg per dose by mouth every 12 hours for 7 days; for children &lt;45 kg, use 2.2 mg/kg body weight per dose</td>
<td>Quinidine gluconate: 10 mg = 6.25 mg quinidine base.</td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clindamycin 7 mg/kg body weight per dose by mouth given every 8 hours for 7 days.</td>
<td>Doxycycline (or tetracycline) should be used in children aged ≥8 years. For patients unable to take oral medication, may give IV. For children &lt;45 kg, give 2.2 mg/kg IV every 12 hours and then switch to oral doxycycline. For children ≥45 kg, use the same dosing as per adults. For IV use, avoid rapid administration.</td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tetracycline 6–12.5 mg/kg body weight per dose every 6 hours (maximum dose 500 mg per dose given 4 times daily) for 7 days</td>
<td>For patients unable to take oral clindamycin, give 10 mg base/kg loading dose IV, followed by 5 mg base/kg IV every 8 hours. Switch to oral clindamycin (oral dose as above) as soon as a patient can take oral medication. For IV use, avoid rapid administration.</td>
</tr>
<tr>
<td></td>
<td><strong>Artesunate 2.4 mg/kg body weight IV bolus at 0, 12, 24, and 48 hours</strong></td>
<td><strong>Drug Interactions:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>PLUS One of the Following:</strong></td>
<td>• Avoid co-administration of quinidine with ritonavir</td>
</tr>
<tr>
<td></td>
<td>• Doxycycline (treatment dosing as above), or Atovaquone-proguanil (treatment dosing as above), or</td>
<td>• Use quinidine with caution with other protease inhibitors</td>
</tr>
<tr>
<td></td>
<td>• Mefloquine 15 mg/kg body weight (maximum 750 mg) by mouth once, then 10 mg/kg body weight (maximum 500 mg) by mouth once given 12 hours later, or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clindamycin (dosing as above)</td>
<td></td>
</tr>
</tbody>
</table>

**Key to Acronyms:** CDC = Centers for Disease Control and Prevention; G6PD = glucose-6-phosphate dehydrogenase; IND = investigational new drug; IV = intravenous; PART = presumptive anti-relapse therapy
## Microsporidiosis (Last updated November 6, 2013; last reviewed November 6, 2013)

### Dosing Recommendations for Preventing and Treating Microsporidiosis

<table>
<thead>
<tr>
<th>Preventive Regimen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prophylaxis</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Not recommended</td>
</tr>
</tbody>
</table>
| **Secondary Prophylaxis** | Disseminated, Non-Ocular Infection or GI Infection Caused by Microsporidia Other Than *E. bieneusi* or *V. corneae*:  
  • Albendazole 7.5 mg/kg body weight (maximum 400 mg/dose) by mouth twice daily  
  **Ocular Infection:**  
  • Topical fumagillin bicyclohexylammonium (Fumidil B) 3 mg/mL in saline (fumagillin 70 μg/mL) eye drops: 2 drops every 2 hours for 4 days, then 2 drops QID (investigational use only in United States) *plus* albendazole 7.5 mg/kg body weight (maximum 400 mg/dose) by mouth twice daily for management of systemic infection | N/A | Criteria For Discontinuing Secondary Prophylaxis:  
  • Continue until sustained immune reconstitution (more than 6 months at CDC immunologic category 1 or 2), or  
  • After initiation of cART and resolution of signs and symptoms |
| **Treatment** | Effective cART Therapy:  
  • Immune reconstitution may lead to microbiologic and clinical response  
  **For Disseminated (Not Ocular) and Intestinal Infection Attributed to Microsporidia Other Than *E. bieneusi* or *V. corneae*:**  
  • Albendazole 7.5 mg/kg body weight (maximum 400 mg/dose) by mouth twice daily  
  **Treatment Duration:**  
  • Continue until sustained immune reconstitution (longer than 6 months at CDC immunologic category 1 or 2) after initiation of cART and resolution of signs and symptoms  
  **For *E. bieneusi* or *V. corneae* infections:**  
  • Fumagillin adult dose 20 mg by mouth 3 times daily, or  
  • TNP-470 (a synthetic analogue of fumagillin) recommended for treatment of infections due to *E. bieneusi* in HIV-infected adults  
  **For Ocular Infection:**  
  • Topical fumagillin bicyclohexylammonium (Fumidil B) 3 mg/mL in saline (fumagillin 70 μg/mL) eye drops: 2 drops every 2 hours for 4 days, then 2 drops QID (investigational use only in United States) *plus* albendazole 7.5 mg/kg body weight (maximum 400 mg/dose) by mouth twice daily for management of systemic infection  
  **Treatment Duration:**  
  • Continue until sustained immune reconstitution (longer than 6 months at CDC immunologic category 1 or 2) after initiation of cART and resolution of signs and symptoms. | N/A | • Supportive care: Hydration, correct electrolyte abnormalities, nutritional support  
  • Fumagillin for systemic use is unavailable in the United States and data on dosing in children are unavailable. Consultation with an expert is recommended. |

**Key to Acronyms:** cART = combination antiretroviral therapy; CDC = Centers for Disease Control and Prevention; GI = gastrointestinal; QID = four times a day
**Mycobacterium avium Complex Disease**  
(Last updated January 8, 2019; last reviewed January 8, 2019)

**Dosing Recommendations for Prevention and Treatment of Mycobacterium avium Complex (MAC)**

<table>
<thead>
<tr>
<th>Preventive Regimen</th>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| **Primary Prophylaxis** | - Clarithromycin 7.5 mg/kg body weight (maximum 500 mg) orally twice daily, or  
- Azithromycin 20 mg/kg body weight (maximum 1200 mg) orally once weekly | - Azithromycin 5 mg/kg body weight (maximum 250 mg) orally once daily  
- Children aged >5 years: rifabutin 300 mg orally once daily with food | Primary Prophylaxis Indicated for Children:  
- Aged <1 year: CD4 count <750 cells/mm³;  
- Aged 1 to <2 years: CD4 count <500 cells/mm³;  
- Aged 2 to <6 years: CD4 count <75 cells/mm³;  
- Aged ≥6 years: CD4 count <50 cells/mm³  
Criteria for Discontinuing Primary Prophylaxis:  
- Do not discontinue in children aged <2 years.  
- After ≥6 months of ART, and:  
  - Aged 2 to <6 years: CD4 count >200 cells/mm³ for ≥3 consecutive months  
  - Aged ≥6 years: CD4 count >100 cells/mm³ for ≥3 consecutive months  
Criteria for Restarting Primary Prophylaxis:  
- Aged 2 to <6 years: CD4 count <200 cells/mm³  
- Aged ≥6 years: CD4 count <100 cells/mm³  
| **Secondary Prophylaxis** (Chronic Suppressive Therapy) | - Clarithromycin 7.5 mg/kg body weight (maximum 500 mg) orally twice daily,  
  plus  
- Ethambutol 15–25 mg/kg body weight (maximum 2.5 g) orally once daily, with or without food  
- Children aged >5 years who received rifabutin as part of initial treatment: Rifabutin 5 mg/kg body weight (maximum 300 mg) orally once daily with food | - Ethambutol 15–25 mg/kg body weight (maximum 2.5 g) orally once daily, with or without food  
- Children aged >5 years who received rifabutin as part of initial treatment: Rifabutin 5 mg/kg body weight (maximum 300 mg) orally once daily with food | Secondary Prophylaxis Indicated:  
- Prior disease  
Criteria for Discontinuing Secondary Prophylaxis  
Fulfillment of All of the Following Criteria:  
- Completed ≥6 months of ART  
- Completed ≥12 months MAC therapy  
- Asymptomatic for signs and symptoms of MAC  
- Aged 2 to <6 years: CD4 count >200 cells/mm³ for ≥6 consecutive months  
- Aged ≥6 years: CD4 count >100 cells/mm³ for ≥6 consecutive months  
Criteria for Restarting Secondary Prophylaxis:  
- Aged 2 to <6 years: CD4 count <200 cells/mm³  
- Aged ≥6 years: CD4 count <100 cells/mm³ |
## Dosing Recommendations for Prevention and Treatment of *Mycobacterium avium* Complex (MAC)

### Table: Preventive Regimen

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| Treatment  | Initial Treatment (≥2 Drugs):  
• Clarithromycin 7.5–15 mg/kg body weight (maximum 500 mg/dose) orally twice daily **plus** ethambutol 15–25 mg/kg body weight (maximum 2.5 g/day) orally once daily  
For Severe Disease, Add:  
• Rifabutin 10–20 mg/kg body weight (maximum 300 mg/day) orally once daily  
If Intolerant to Clarithromycin:  
• Azithromycin 10–12 mg/kg body weight (maximum 500 mg/day) orally once daily  
If Rifabutin Cannot Be Administered and a Third Drug is Needed in Addition to a Macrolide and Ethambutol, or if a Fourth Drug is Needed in Addition to Rifabutin for Patients with More Severe Symptoms or Disseminated Disease:  
• Ciprofloxacin 10–15 mg/kg orally twice daily (maximum 1.5 g/day), or  
• Levofloxacin 500 mg orally once daily, or  
• Amikacin 15–30 mg/kg body weight IV in 1 or 2 divided doses (maximum 1.5 g/day) |  | Combination therapy with a minimum of 2 drugs is recommended for ≥12 months.  
Clofazimine is associated with increased mortality in adults with HIV infection and should not be used.  
Children receiving ethambutol who are old enough to undergo routine eye testing should have monthly monitoring of visual acuity and color discrimination.  
Fluoroquinolones (e.g., ciprofloxacin and levofloxacin) are not labeled for use in children aged <18 years because of concerns regarding potential effects on cartilage; use in children aged <18 years requires an assessment of potential risks and benefits.  
Chronic suppressive therapy (secondary prophylaxis) is recommended in children and adults following initial therapy. |

---

**Key to Acronyms:** ART = antiretroviral therapy; CD4 = CD4 T lymphocyte; MAC = *Mycobacterium avium* complex; IV = intravenous
### Table: Dosing Recommendations for Preventing and Treating TB in HIV-infected Children  (page 1 of 2)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-exposure Source Case Drug Susceptible:</td>
<td>Isoniazid 10–15 mg/kg body weight (maximum 300 mg/day) by mouth daily for 9 months</td>
<td>• If adherence with daily isoniazid cannot be ensured, consider isoniazid 20–30 mg/kg body weight (maximum 900 mg/day) by mouth 2 times a week by DOT for 9 months</td>
<td>Drug-drug interactions with cART should be considered for all rifamycin containing alternatives.</td>
</tr>
<tr>
<td>Source Case Drug Resistant:</td>
<td>Consult expert and local public health authorities.</td>
<td>• Isoniazid 10–15 mg/kg body weight (maximum 300 mg/day) and rifampin 10–20 mg/kg body weight (maximum 600 mg/day) by mouth daily for 3–4 months</td>
<td>Indication:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Rifampin 10–20 mg/kg body weight (maximum 600 mg/day) by mouth daily for 4–6 months</td>
<td>• Positive TST (TST ≥ 5 mm) or IGRA without previous TB treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Close contact with any infectious TB case (repeated exposures warrant repeated post-exposure prophylaxis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• TB disease must be excluded before starting treatment.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• No indication for pre-exposure and post-treatment prophylaxis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug-drug interactions with cART should be considered for all rifamycin containing alternatives.</td>
<td>Criteria for Discontinuing Prophylaxis:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Only with documented severe adverse event, which is exceedingly rare.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight once daily (maximum 25–50 mg/day) with isoniazid; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Co-trimoxazole prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Co-trimoxazole prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Co-trimoxazole prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Co-trimoxazole prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Co-trimoxazole prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjunctive Treatment:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Co-trimoxazole prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pyridoxine 1–2 mg/kg body weight/day (maximum 25–50 mg/day) with isoniazid or cycloserine/terizidone or, if malnourished; pyridoxine supplementation is recommended for exclusively breastfed infants and for children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies, including all symptomatic HIV-infected children; and pregnant adolescents and women.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Only DOT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If cART-naive, start TB therapy immediately and initiate cART within 2–8 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Already on cART; review to minimize potential toxicities and drug-drug interactions; start TB treatment immediately.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Potential drug toxicity and interactions should be reviewed at every visit.</td>
</tr>
</tbody>
</table>
Table: Dosing Recommendations for Preventing and Treating TB in HIV-infected Children  (page 2 of 2)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment, continued</td>
<td>• Lymph node TB—treat as minimal intrathoracic disease</td>
<td></td>
<td>by tapering) with CNS disease or pericardial effusion; may be considered with pleural effusions, severe airway compression, or severe IRIS.</td>
</tr>
<tr>
<td></td>
<td>• Bone or joint disease—consider extending continuation phase to 10 months (for total duration of therapy of 12 months).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB Meningitis:</td>
<td>• As alternative to ethambutol or streptomycin, 20–40 mg/kg body weight (maximum 1 g/day) IM once daily—during intensive phase, consider ethionamide, 15–20 mg/kg body weight by mouth (maximum 1 g/day), initially divided into 2 doses until well tolerated</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consider extending continuation phase to 10 months (for total duration of therapy of 12 months).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss with an expert.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug-Resistant TB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDR-TB</td>
<td>• Therapy should be based on resistance pattern of child (or of source case where child’s isolate is not available); consult an expert.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment Duration</td>
<td>• 18–24 months after non-bacteriological diagnosis or after culture conversion; ≥12 months if minimal disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss with an expert.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key to Acronyms: cART = combined antiretroviral therapy; CNS = central nervous system; DOT = directly observed therapy; FDA = Food and Drug Administration; IGRA = interferon-gamma release assay; IM = intramuscular; IRIS = immune reconstitution inflammatory syndrome; IV = intravenous; MDR-TB = multi-drug-resistant tuberculosis; TB = tuberculosis; TST = tuberculin skin test

References:


Centers for Disease Control and Prevention. Treatment of Tuberculosis. MMWR 52(RR11);1-77. 2003.


## Pneumocystis jirovecii Pneumonia

**Last updated November 6, 2013; last reviewed November 6, 2013**

### Dosing Recommendations for Prevention and Treatment of Pneumocystis Pneumonia (page 1 of 2)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| **Primary Prophylaxis**  | • **TMP-SMX (Cotrimoxazole):** TMP 2.5–5 mg/kg body weight/dose with SMX 12.5–25 mg/kg body weight/dose twice per day. Dosing based on TMP component.  
  • The total daily dose should not exceed 320 mg TMP and 1600 mg SMX. Several dosing schemes have been used successfully—  
  • Given 3 days per week on consecutive days or on alternate days  
  • Given 2 days per week on consecutive days or on alternate days  
  • Given every day (total daily dose of TMP 5–10 mg/kg body weight given as a single dose each day) | **Dapsone**  
  **Children aged ≥1 months:**  
  • 2 mg/kg body weight (maximum 100 mg) by mouth once daily or 4 mg/kg body weight (maximum 200 mg) by mouth once weekly  
  **Atovaquone**  
  **Children Aged 1–3 Months and >24 Months–12 Years:**  
  • 30-40 mg/kg body weight/dose by mouth once daily with food  
  **Children Aged 4–24 Months:**  
  • 45 mg/kg body weight/dose by mouth once daily with food  
  **Children Aged ≥13 Years:**  
  • 1500 mg (10 cc oral yellow suspension) per dose by mouth once daily  
  **Aerosolized Pentamidine**  
  **Children Aged ≥5 Years:**  
  • 300 mg every month via Respigrad II™ nebulizer (manufactured by Marquest; Englewood, Colorado) | **Primary Prophylaxis Indicated For:**  
  • All HIV-infected or HIV-indeterminate infants from aged 4–6 weeks to 12 months regardless of CD4 cell count/percentage  
  • HIV-infected children aged 1 to <6 years with CD4 count <500 cells/mm<sup>3</sup> or CD4 percentage <15%; HIV-infected children aged 6–12 years with CD4 count <200 cells/mm<sup>3</sup> or CD4 percentage <15%  
  **Criteria for Discontinuing Primary Prophylaxis:**  
  **Note:** Do not discontinue in HIV-infected children aged <1 year  
  **After ≥6 Months of cART:**  
  • Aged 1 to <6 years; CD4 percentage ≥15% or CD4 count is ≥500 cells/mm<sup>3</sup> for >3 consecutive months, or  
  • Aged ≥6 years, CD4 percentage ≥15% or CD4 count is ≥200 cells/mm<sup>3</sup> for >3 consecutive months  
  **Criteria for Restarting Primary Prophylaxis:**  
  • Aged 1 to <6 years with CD4 percentage <15% or CD4 count <500 cells/mm<sup>3</sup>  
  • Aged ≥6 years with CD4 percentage <15% or CD4 count <200 cells/mm<sup>3</sup> |
| **Secondary Prophylaxis** | Same as for primary prophylaxis.                                             | Same as for primary prophylaxis.                                             | **Secondary Prophylaxis Indicated For:**  
  • Children with prior episode of PCP  
  **Criteria for Discontinuing Secondary Prophylaxis:**  
  • Same as for primary prophylaxis  
  **Criteria for Restarting Secondary Prophylaxis:**  
  • Same as for primary prophylaxis |
| **Prior PCP**             |                                                                              |                                                                              |                                                                                        |
## Dosing Recommendations for Prevention and Treatment of Pneumocystis Pneumonia

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment</strong></td>
<td>TMP-SMX 3.75–5 mg/kg body weight/dose TMP (based on TMP component) every 6 hours IV or orally given for 21 days (followed by secondary prophylaxis dosing)</td>
<td>If TMP-SMX-intolerant or Clinical Treatment Failure After 5–7 Days of TMP-SMX Therapy</td>
<td>After acute pneumonitis resolved in mild-moderate disease, IV TMP-SMX can be changed to oral. For oral administration, total daily dose of TMP-SMX can also be administered in 3 divided doses (every 8 hours).</td>
</tr>
<tr>
<td>Pentamidine:</td>
<td>4 mg/kg body weight/dose IV/IM once daily is the first choice alternative regimen. <strong>Note:</strong> Pentamidine can be changed to atovaquone after 7–10 days IV therapy.</td>
<td>Pentamidine can be changed to atovaquone after 7–10 days IV therapy.</td>
<td></td>
</tr>
<tr>
<td><strong>Atovaquone</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Daily Dosing:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Children aged 1–3 months and &gt;24 months–12 years: 30–40 mg/kg body weight/dose by mouth once daily with food</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Children aged 4–24 months: 45 mg/kg body weight/dose by mouth once daily with food</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Twice-Daily Dosing</strong> *:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Children aged ≥13 years: 750 mg/dose by mouth twice daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dapsone</strong></td>
<td>2 mg/kg body weight by mouth once daily (maximum 100 mg/day) plus trimethoprim 5 mg/kg body weight by mouth every 8 hours has been used in adults but data in children are limited.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primamquine base</strong></td>
<td>0.3 mg/kg body weight by mouth once daily (maximum 30 mg/day) plus clindamycin 10 mg/kg body weight/dose IV or by mouth (maximum 600 mg given IV and 300–450 mg given orally) every 6 hours has been used in adults, but data in children are not available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Indications for Corticosteroids:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• PaO₂ &lt;70 mm Hg at room air or alveolar-arterial oxygen gradient &gt;35 mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prednisone Dose:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 1 mg/kg body weight/dose by mouth twice daily for 5 days, then</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 0.5–1 mg/kg body weight/dose by mouth twice daily for 5 days, then</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 0.5 mg/kg body weight by mouth once daily for days 11 to 21.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alternative Corticosteroid Regimens Include:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Adult dosage of prednisone: 40 mg/dose twice daily on days 1–5, 40 mg/dose once daily on days 6–10, 20 mg/dose once daily on days 11–21, and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Methylprednisolone IV 1 mg/kg/dose every 6 hours on days 1–7, 1 mg/kg/dose twice daily on days 8–9, 0.5 mg/kg/dose twice daily on days 10 and 11, and 1 mg/kg/dose once daily on days 12–16.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic suppressive therapy (secondary prophylaxis) with TMP/SMX is recommended in children and adults following initial therapy (see Secondary Prophylaxis).</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Some experts use twice-daily dosing of atovaquone as alternative treatment for PCP in children aged <12 years:

- Children aged 1–3 months and >24 months to 12 years: 15–20 mg/kg body weight/dose by mouth twice daily with food
- Children aged 4–24 months: 22.5 mg/kg body weight/dose by mouth twice daily with food.

**Key to Acronyms:** cART = combination antiretroviral therapy; CD4 = CD4 T lymphocyte cell; IM = intramuscular; IV = intravenous; PCP = Pneumocystis jiroveci pneumonia; TMP-SMX = trimethoprim-sulfamethoxazole

**Note:** Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for products or indications. Specifically, the terms safe and effective might not be synonymous with the FDA-defined legal standards for product approval.
### Dosing Recommendations for Prevention and Treatment of Syphilis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| **Primary Prophylaxis** | N/A          | N/A         | **Primary Prophylaxis Indicated for:**  
|                       |              |             | • N/A                    |
|                       |              |             | **Criteria for Discontinuing Primary Prophylaxis:**  
|                       |              |             | • N/A                    |
|                       |              |             | **Criteria for Restarting Primary Prophylaxis:**  
|                       |              |             | • N/A                    |
| **Secondary Prophylaxis** | N/A          | N/A         | **Secondary Prophylaxis Indicated:**  
|                       |              |             | • N/A                    |
|                       |              |             | **Criteria For Discontinuing Secondary Prophylaxis:**  
|                       |              |             | • N/A                    |
|                       |              |             | **Criteria For Restarting Secondary Prophylaxis:**  
|                       |              |             | • N/A                    |
### Preventive Regimen

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Congenital

**Proven or Highly Probable Disease:**
- Aqueous crystalline penicillin G 100,000–150,000 units/kg body weight per day, administered as 50,000 units/kg body weight per dose IV every 12 hours for the first 7 days of life, and then every 8 hours for 10 days
- If diagnosed after 1 month of age, aqueous penicillin G 200,000–300,000 unit/kg body weight per day, administered as 50,000 units/kg body weight per dose IV every 4–6 hours (maximum 18–24 million units per day) for 10 days

**Possible Disease:**
- Treatment options are influenced by several factors, including maternal treatment, titer, and response to therapy; and infant physical exam, titer, and test results. Scenarios that include variations of these factors are described and treatment recommendations are provided in detail on pages 36–37 of the Centers for Disease Control STD Treatment Guidelines, 2010.

#### Acquired

**Early Stage (Primary, Secondary, Early Latent):**
- Benzathine penicillin 50,000 units/kg body weight (maximum 2.4 million units) IM for 1 dose

**Late Latent:**
- Benzathine penicillin 50,000 units/kg body weight (maximum 2.4 million units) IM once weekly for 3 doses

**Neurosyphilis (Including Ocular):**
- Aqueous penicillin G 200,000–300,000 units/kg body weight per day administered as 50,000 units/kg body weight per dose IV every 4–6 hours (maximum 18–24 million units per day) for 10–14 days

**Congenital**

**Proven or Highly Probable Disease (Less Desirable if CNS Involvement):**
- Procaine penicillin G 50,000 units/kg body weight IM once daily for 10 days

**Possible Disease:**
- Treatment options are influenced by several factors, including maternal treatment, titer, and response to therapy; and infant physical exam, titer, and test results. Scenarios that include variations of these factors are described and treatment recommendations are provided in detail on pages 36–37 of the Centers for Disease Control STD Treatment Guidelines, 2010.

For treatment of congenital syphilis, repeat the entire course of treatment if >1 day of treatment is missed.

Examinations and serologic testing for children with congenital syphilis should occur every 2–3 months until the test becomes non-reactive or there is a fourfold decrease in titer. Children with increasing titers or persistently positive titers (even if low levels) at ages 6–12 months should be evaluated and considered for re-treatment.

In the setting of maternal and possible infant HIV infection, the more conservative choices among scenario-specific treatment options may be preferable.

Children and adolescents with acquired syphilis should have clinical and serologic response monitored at 3, 6, 9, 12, and 24 months after therapy.

---

**Key to Acronyms:** CDC = Centers for Disease Control and Prevention; IM = intramuscular; IV = intravenous; STD = sexually transmitted disease
### Dosing Recommendations for the Prevention and Treatment of Toxoplasmosis

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| **Primary Prophylaxis**   | **First Choice** TMP-SM X 150/750 mg/m² body surface area once daily by mouth | **For Children Aged ≥1 Month:**  
  - Dapsone 2 mg/kg body weight or 15 mg/m² body surface area (maximum 25 mg) by mouth once daily, **plus**  
  - Pyrimethamine 1 mg/kg body weight (maximum 25 mg) by mouth once daily, **plus**  
  - Leucovorin 5 mg by mouth every 3 days  
  **For Children Aged 1–3 Months and >24 Months:**  
  - Atovaquone 30 mg/kg body weight by mouth once daily  
  **Children Aged 4–24 Months:**  
  - Atovaquone 45 mg/kg body weight by mouth once daily, with or without pyrimethamine 1 mg/kg body weight or 15 mg/m² body surface area (maximum 25 mg) by mouth once daily, **plus**  
  - Leucovorin 5 mg by mouth every 3 days  | **Primary Prophylaxis Indicated For:**  
  IgG Antibody to Toxoplasma and Severe Immunosuppression:  
  - HIV-infected children aged <6 years with CD4 percentage <15%; HIV-infected children aged ≥6 years with CD4 count <100 cells/mm³  
  **Criteria for Discontinuing Primary Prophylaxis:**  
  - Note: Do not discontinue in children aged <1 year  
  - After ≥6 months of cART, **and**  
  - Aged 1 to <6 years; CD4 percentage is ≥15% for >3 consecutive months  
  - Aged ≥6 years; CD4 count >200 cells/mm³ for >3 consecutive months  
  **Criteria for Restarting Primary Prophylaxis:**  
  - Aged 1 to <6 years with CD4 percentage <15%  
  - Aged ≥6 years with CD4 count <100 to 200 cells/mm³  |
| **Secondary Prophylaxis** | **(Suppressive Therapy)**  
  - Sulfadiazine 42.5–60 mg/kg body weight per dose twice daily* (maximum 2–4 g per day) by mouth, **plus**  
  - Pyrimethamine 1 mg/kg body weight or 15 mg/m² body surface area (maximum 25 mg) by mouth once daily, **plus**  
  - Leucovorin 5 mg by mouth once every 3 days  | **Clindamycin 7–10 mg/kg body weight per dose by mouth 3 times daily, **plus****  
  **Pyrimethamine 1 mg/kg body weight or 15 mg/m² body surface area (maximum 25 mg) by mouth once daily, plus**  
  **Leucovorin 5 mg by mouth once every 3 days**  
  **Children Aged 1–3 Months and >24 Months:**  
  - Atovaquone 30 mg/kg body weight by mouth once daily  
  - Leucovorin, 5 mg by mouth every 3 days  
  **TMP-SMX, 150/750 mg/m² body surface area once daily by mouth**  | **Secondary Prophylaxis Indicated:**  
  Prior toxoplasmic encephalitis  
  **Note:** Alternate regimens with very limited data in children. TMP-SMX only to be used if patient intolerant to other regimens  
  **Criteria for Discontinuing Secondary Prophylaxis**  
  **If All of the Following Criteria are Fulfilled:**  
  - Completed ≥6 months of cART, completed initial therapy for TE, asymptomatic for TE, **and**  |
## Dosing Recommendations for the Prevention and Treatment of Toxoplasmosis (page 2 of 3)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
</table>
| **Secondary Prophylaxis (Suppressive Therapy), continued** | | Children Aged 4–24 Months: **First Choice** | • Atovaquone 45 mg/kg body weight by mouth once daily, with or without pyrimethamine 1 mg/kg body weight or 15 mg/m² body surface area (maximum 25 mg) by mouth once daily. **plus**
• Leucovorin, 5 mg by mouth every 3 days
• TMP-SMX, 150/750 mg/m² body surface area once daily by mouth |
| | | **Secondary** | • Aged 1 to < 6 years; CD4 percentage ≥15% for ≥6 consecutive months
• Aged ≥6 years; CD4 cell count >200 cells/mm³ for ≥6 consecutive months |
| | | **Criteria For Restarting Secondary Prophylaxis:** | • Aged 1 to <6 years with CD4 percentage <15%
• Aged ≥6 years with CD4 cell count <200 cells/mm³ |
| **Treatment** | | **Congenital Toxoplasmosis:** | For infants born to mothers with symptomatic Toxoplasma infection during pregnancy, empiric therapy of the newborn should be strongly considered irrespective of the mother’s treatment during pregnancy. |
| | **Congenital Toxoplasmosis:** | **Acquired Toxoplasmosis** | For infants born to mothers with symptomatic Toxoplasma infection during pregnancy, empiric therapy of the newborn should be strongly considered irrespective of the mother’s treatment during pregnancy. |
| | • Pyrimethamine loading dose—2 mg/kg body weight by mouth once daily for 2 days, then 1 mg/kg body weight by mouth once daily for 2–6 months, then 1 mg/kg body weight by mouth 3 times weekly. **plus**
• Leucovorin (folinic acid) 10 mg by mouth or IM with each dose of pyrimethamine. **plus**
• Sulfadiazine 50 mg/kg body weight by mouth twice daily |
| | | **Acute Induction Therapy (Followed by Chronic Suppressive Therapy):** | • Pyrimethamine: loading dose—2 mg/kg body weight (maximum 50 mg) by mouth once daily for 3 days, then 1 mg/kg body weight (maximum 25 mg) by mouth once daily. **plus**
• Sulfadiazine 25–50 mg/kg body weight (maximum 1–1.5 g/dose) by mouth per dose 4 times daily, **plus**
• Leucovorin 10–25 mg by mouth once daily, followed by chronic suppressive therapy |
| | **Treatment Duration:** | **Treatment Duration (Followed by Chronic Suppressive Therapy):** | • ≥6 weeks (longer duration if clinical or radiologic disease |
| | **For Sulfonamide-Intolerant Patients:** | | For sulfonamide-intolerant patients: • Clindamycin 5–7.5 mg/kg body weight (maximum 600 mg/dose) by mouth or IV per dose given 4 times a day can be substituted for sulfadiazine combined with pyrimethamine and leucovorin |
| | • Pyrimethamine use requires CBC monitoring at least weekly while on daily dosing and at least monthly while on less than daily dosing. |
| | • TMP-SMX—TMP 5 mg/kg body weight plus SMX 25 mg/kg body weight per dose IV or by mouth given twice daily has been used as an alternative to pyrimethamine-sulfadiazine in adults, but has not been studied in children. |
| | • Atovaquone (for adults, 1.5 g by mouth twice daily—double the prophylaxis dose) in regimens combined with pyrimethamine/leucovorin, with sulfadiazine alone, or as a single agent in patients intolerant to both pyrimethamine and sulfadiazine, has been used in adults, but these regimens have not been studied in children. |
| | • Azithromycin (for adults, 900–1,200 mg/day, corresponding to 20 mg/kg/day in children) has also been used in adults combined with pyrimethamine-sulfadiazine, but has not been studied in children. |
| | • Corticosteroids (e.g., prednisone, dexamethasone) have been used in children with CNS disease when CSF protein is very elevated (>1,000 mg/dL) or there are focal lesions with significant mass effects, with discontinuation as soon as clinically feasible. |
| | • Anticonvulsants should be administered to patients with a history of seizures and
**Dosing Recommendations for the Prevention and Treatment of Toxoplasmosis** (page 3 of 3)

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment, continued</strong></td>
<td>is extensive or response in incomplete at 6 weeks)</td>
<td></td>
<td>continued through the acute treatment; but should not be used prophylactically.</td>
</tr>
</tbody>
</table>

*Note: Sulfadiazine may be given as 2–4 equal doses per day as long as the total daily dose is 85–120 mg/kg body weight.

**Key to Acronyms:** cART = combination antiretroviral therapy; CBC = complete blood count; CD4 = CD4 T lymphocyte; CNS = central nervous system; CSF = cerebrospinal fluid; IgG = Immunoglobulin G; IM = intramuscular; IV = intravenous; TE = toxoplastic encephalitis; TMP-SMX = trimethoprim-sulfamethoxazole
# Dosing Recommendations for Preventing and Treating Varicella-Zoster Virus

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-Exposure Prophylaxis</strong></td>
<td>Varicella vaccine</td>
<td>N/A</td>
<td>See Figures 1 and 2 for detailed vaccine recommendations.</td>
</tr>
</tbody>
</table>
| **Primary (Post-Exposure) Prophylaxis** | VariZIG 125 IU/10 kg body weight IM (maximum 625 IU), administered ideally within 96 hours (potentially beneficial up to 10 days) after exposure | • If VariZIG cannot be administered within 96 hours (up to 10 days), IVIG 400 mg/kg body weight, administered once should be considered. IVIG should ideally be administered within 96 hours of exposure.  
• When passive immunization is not possible, some experts recommend prophylaxis with acyclovir 20 mg/kg body weight/dose (maximum dose 800 mg), administered QID for 7 days, beginning 7–10 days after exposure. | **Primary Post-Exposure Prophylaxis Indicated for:**  
• Patients with substantial exposure to varicella or zoster with no verified history of varicella or zoster or who are seronegative for VZV on a sensitive, specific antibody assay or who lack evidence of vaccination. Many experts limit this recommendation to varicella or zoster-exposed HIV-infected children who are considered to be severely immunocompromised, (i.e., in CDC Immunologic Category 3), especially if also classified as CDC Clinical Category C and experiencing a high HIV RNA plasma viral load (BIII).  
• Some experts start acyclovir at first appearance of rash.  
**Note:** To obtain VariZIG, contact FFF Enterprises at 1-800-843-7477 or [http://www.fffenterprises.com](http://www.fffenterprises.com). |
| **Secondary Prophylaxis**       | N/A                                 | N/A         | There is no indication for secondary prophylaxis                                         |

<table>
<thead>
<tr>
<th>Indication</th>
<th>First Choice</th>
<th>Alternative</th>
<th>Comments/Special Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chickenpox</td>
<td><strong>Children with No or Moderate Immune Suppression (CDC Immunologic Categories 1 and 2) and Mild Varicella Disease:</strong></td>
<td><strong>Patients Unresponsive to Acyclovir:</strong></td>
<td>In children ≥1 year of age, some experts base IV acyclovir dosing on body surface area (500 mg/m² body surface area/dose IV every 8 hours) instead of body weight. Valacyclovir is approved for use in adults and adolescents with zoster at 1 g/dose by mouth TID for 7 days; the same dose has been used for varicella infections. Data on dosing in children are limited and there is no pediatric preparation, although 500 mg capsules can be extemporaneously compounded to make a suspension to administer 20 mg/kg body weight/dose (maximum dose 1 g) given TID (see prescribing information). Famciclovir is approved for use in adults and adolescents with zoster at 500 mg/dose by mouth TID for 7 days; the same dose has been used for varicella infections. There is no pediatric preparation and data on dosing in children are limited; can be used by adolescents able to receive adult dosing. Involvement of an ophthalmologist with experience in managing herpes zoster ophthalmicus and its complications in children is strongly recommended when ocular involvement is evident. Optimal management of PORRN has not been defined.</td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 20 mg/kg body weight/dose by mouth (max 800 mg/dose) QID for 7–10 days and until no new lesions for 48 hours</td>
<td>• Acyclovir 10 mg/kg body weight 500 mg/m²/dose IV every 8 hours for 7–10 days and until no new lesions for 48 hours</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children with Severe Immune Suppression (CDC Immunologic Category 3):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 10 mg/kg body weight 500 mg/m²/dose IV every 8 hours for 7–10 days and until no new lesions for 48 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td><strong>Children with Uncomplicated Zoster:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 20 mg/kg body weight/dose (max 800 mg/dose) by mouth QID for 7–10 days.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children with Severe Immunosuppression (CDC Immunologic Category 3), Trigeminal or Sacral Nerve Involvement, Extensive Multidermatomal, or Disseminated Zoster:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 10 mg/kg body weight/dose IV every 8 hours until cutaneous lesions and visceral disease are clearly resolving, then can switch to acyclovir by mouth to complete a 10- to 14-day course</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children with Progressive Outer Retinal Necrosis:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ganciclovir 5 mg/kg body weight/dose IV every 12 hours, <strong>plus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Foscarnet 90 mg/kg body weight/dose IV every 12 hours, <strong>plus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ganciclovir 2 mg/0.05 mL intravitreal twice weekly and/or Foscarnet 1.2 mg/0.05 mL intravitreal twice weekly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children with ARN:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Acyclovir 10–15 mg/kg body weight/dose IV every 8 hours daily for 10–14 days, <strong>followed by</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral valacyclovir 1 g/dose TID for 4–6 weeks (for children old enough to receive adult dose). Alternative oral acyclovir dose: 20 mg/kg body weight/dose QID for 4–6 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key to Acronyms:** ARN = acute retinal necrosis; CDC = Centers for Diseases Control and Prevention; IM = intramuscular; IU = international units; IV = intravenous; IVIG = intravenous immunoglobulin; PORRN = progressive outer retinal necrosis; QID = four times a day; TID = three times daily; VarZIG = varicella zoster immune globulin; VZV = varicella zoster virus